WO2016067968A1 - ミトコンドリア機能改善剤、及び老化防止用組成物 - Google Patents
ミトコンドリア機能改善剤、及び老化防止用組成物 Download PDFInfo
- Publication number
- WO2016067968A1 WO2016067968A1 PCT/JP2015/079543 JP2015079543W WO2016067968A1 WO 2016067968 A1 WO2016067968 A1 WO 2016067968A1 JP 2015079543 W JP2015079543 W JP 2015079543W WO 2016067968 A1 WO2016067968 A1 WO 2016067968A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- extract
- sodium
- group
- oil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/03—Preparation of carboxylic acid esters by reacting an ester group with a hydroxy group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/317—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
Definitions
- the present invention relates to a mitochondrial function improving agent and an anti-aging composition.
- Mitochondria are organelles responsible for the production of energy in the cell, and produce ATP by consuming oxygen by oxidative phosphorylation in the electron transport system. Protons generated during this reaction process are pumped between the outer and inner mitochondrial membranes (intermembrane space), creating a potential difference (mitochondrial membrane potential). Next, protons in the intermembrane space are utilized by ATP synthase to produce ATP. In addition, stress such as DNA damage caused by ultraviolet irradiation changes the mitochondrial membrane potential via p53 and BCL family proteins, and induces cell death called apoptosis.
- Non-Patent Documents 1 and 2 Aged cells and cells damaged by ultraviolet rays generate active oxygen and lipid peroxidation products (Non-Patent Documents 1 and 2), and increase in apoptosis is accompanied by a decrease in energy production in mitochondria.
- Non-patent Document 3 mitochondria are thought to be closely related to aging and photoaging. It is considered that cell activation can be achieved by improving the function of mitochondria in aging cells or cells damaged by stress such as ultraviolet rays. So far, sphingomyelin and glutathione as an antioxidant have been reported as mitochondrial function improving agents (Patent Document 1, Non-Patent Document 4), but the effect is still not sufficient.
- an object of the present invention is to provide a mitochondrial function improving agent capable of improving mitochondrial function, and an anti-aging composition that is effective in preventing skin aging and improving symptoms.
- R 1 and R 2 each independently represent a hydrogen atom or any group selected from the group represented by the following formula (Ia) (provided that R 1 and R 2 are simultaneously X 1 to X 3 each independently represent a nitrogen or oxygen atom, and R 3 , R 4 , R 5 , R 3 ′ , R 4 ′ , and R 5 ′ represent each Independently represents a hydrogen atom, or a chain hydrocarbon group having 1 to 30 carbon atoms which may have a branched or unsaturated bond (provided that X 1 , X 2 and X 3 are each an oxygen atom, , There is no corresponding R 3 ′ , R 4 ′ , R 5 ′ ).
- R 6 to R 8 are each independently a hydrogen atom, an aryl group, or a chain hydrocarbon group having 1 to 30 carbon atoms, which may have a branched, unsaturated bond or substituent. Represents.
- R 6 is a chain hydrocarbon group having 7 to 23 carbon atoms which may have a branch, an unsaturated bond or a substituent
- R 7 and R 8 are The agent for improving mitochondrial function according to [1] above, which is independently a hydrogen atom, or a chain hydrocarbon group having 8 to 24 carbon atoms, which may have a branched, unsaturated bond or substituent.
- X 1 to X 3 are all oxygen atoms
- R 3 to R 5 are each independently a hydrogen atom, or a carbon that may have a branched or unsaturated bond.
- a hydrocarbon group, and R 7 and R 8 are each independently a hydrogen atom, or a chain hydrocarbon group having 8 to 24 carbon atoms, which may have a branched, unsaturated bond or substituent.
- the mitochondrial function improving agent according to the above [1].
- R 2 is a hydrogen atom
- X 1 to X 3 are all oxygen atoms
- R 3 to R 5 are all hydrogen atoms
- R 6 is a chain hydrocarbon group having 13 to 21 carbon atoms, which may have a branch, an unsaturated bond or a substituent.
- R 2 is a hydrogen atom
- X 1 to X 3 are all oxygen atoms
- R 3 to R 5 each independently have a hydrogen atom or a branched or unsaturated bond.
- R 6 in the formula (Ia) Is a mitochondrial function improving agent according to the above [1], which is a chain hydrocarbon group having 13 to 21 carbon atoms, which may have a branch, an unsaturated bond or a substituent.
- hydroxycitric acid derivative or a salt thereof is reacted with an alcohol in a solvent with hydroxycitric acid and / or an alkali metal salt thereof and / or an alkaline earth metal salt thereof to obtain a hydroxycitric acid (tri) ester.
- a first process to manufacture Reacting the aliphatic carboxylic acid derivative with the compound obtained in the first step, and esterifying the hydroxyl group of the compound obtained in the first step; [1] to [1] which are produced by a method comprising a third step of cleaving a part or all of the ester bond sites formed in the first step among the ester bond sites of the compound obtained in the second step.
- the method for producing a mitochondrial function improving agent according to any one of [6].
- R 1 and R 2 each independently represent a hydrogen atom or any group selected from the group represented by the following formula (Ia) (provided that R 1 and R 2 are simultaneously X 1 to X 3 each independently represent a nitrogen or oxygen atom, and R 3 , R 4 , R 5 , R 3 ′ , R 4 ′ , and R 5 ′ represent each Independently represents a hydrogen atom, or a chain hydrocarbon group having 1 to 30 carbon atoms which may have a branched or unsaturated bond (provided that X 1 , X 2 and X 3 are each an oxygen atom, , There is no corresponding R 3 ′ , R 4 ′ , R 5 ′ ).
- R 6 to R 8 are each independently a hydrogen atom, an aryl group, or a chain hydrocarbon group having 1 to 30 carbon atoms, which may have a branched, unsaturated bond or substituent. Represents.
- mitochondrial function can be improved.
- the anti-aging composition of the present invention is useful for preventing or improving aging of cells and skin tissues including wrinkles and tarmi formation.
- the mitochondrial function improving agent of the present invention contains a hydroxycitric acid derivative represented by the following formula (I) or a salt thereof as an active ingredient.
- R 1 and R 2 each independently represent a hydrogen atom or any group selected from the group represented by the following formula (Ia) (provided that R 1 and R 2 are simultaneously X 1 to X 3 each independently represent a nitrogen or oxygen atom, and R 3 , R 4 , R 5 , R 3 ′ , R 4 ′ , and R 5 ′ represent each Independently represents a hydrogen atom, or a chain hydrocarbon group having 1 to 30 carbon atoms which may have a branched or unsaturated bond (provided that X 1 , X 2 and X 3 are each an oxygen atom, , Corresponding R 3 ′ , R 4 ′ and R 5 ′ do not exist.)
- R 6 to R 8 are each independently a hydrogen atom, an aryl group, or a chain hydrocarbon group having 1 to 30 carbon atoms, which may have a branched, unsaturated bond or substituent. Represents.
- the hydroxycitric acid derivative according to the mitochondrial function improving agent of the present invention is a compound represented by the following formula (I).
- R 1 and R 2 each independently represent a hydrogen atom or any group selected from the group represented by the following formula (Ia) (provided that R 1 and R 2 Are not hydrogen atoms at the same time.)
- the at least one of R 1 and R 2 is preferably any group selected from the group represented by the formula (Ia), one of R 1 and R 2 thereof It may be a group, and both may be these groups.
- R 1 and R 2 is these groups
- R 1 is any group selected from the group represented by the above formula (Ia)
- R 2 An embodiment in which is a hydrogen atom is more preferred.
- R 6 to R 8 are each independently a hydrogen atom, an aryl group, or a chain hydrocarbon group having 1 to 30 carbon atoms, which may have a branched, unsaturated bond or substituent. Represents.
- Examples of the aryl group include a phenyl group, a naphthyl group, a furyl group, a thienyl group, and a pyridyl group.
- Examples of the chain hydrocarbon group having 1 to 30 carbon atoms which may have a branch, an unsaturated bond or a substituent include, for example, a part of acyl groups described later as examples of R 1 and / or R 2. The constituents are listed.
- R 6 to R 8 are each independently a hydrogen atom, or a chain hydrocarbon group having 1 to 30 carbon atoms, which may have a branched, unsaturated bond or substituent. preferable.
- R 6 is a branched hydrocarbon group having 7 to 23 carbon atoms, preferably 13 to 21 carbon atoms, more preferably branched, optionally having a branch, an unsaturated bond, or a substituent.
- any group selected from the group represented by the formula (Ia) is desirably a group having 8 to 24 carbon atoms, preferably 14 to 22 carbon atoms.
- R 6 , R 7 and R 8 include groups specifically shown as R 3 , R 4 , R 5 , R 3 ′ , R 4 ′ and R 5 ′ described later.
- R 1 and / or R 2 in the above formula (I) is a hexanoyl group, 2-methylpentanoyl group, 3-methylpentanoyl group Group, 4-methylpentanoyl group, 2-ethylbutanoyl group, heptanoyl group, 2-methylhexanoyl group, 3-methylhexanoyl group, 4-methylhexanoyl group, 2-ethylpentanoyl group, 3-ethyl Pentanoyl group, octanoyl group, 2-methylheptanoyl group, 3-methylheptanoyl group, 4-methylheptanoyl group, 5-methylheptanoyl group, 6-methyl
- R 1 and / or R 2 in formula (I) is an octanoyl group, a decanoyl group, an undecanoyl group, a dodecanoyl group, a hexadecanoyl group, an octadecanoyl group, or an isostearyl group.
- a compound that is any of them is mentioned.
- More preferable examples include compounds in which R 1 is any one of an octanoyl group, a decanoyl group, an undecanoyl group, a dodecanoyl group, a hexadecanoyl group, an octadecanoyl group, and an isostearyl group, and R 2 is a hydrogen atom.
- R 1 is any one of an octanoyl group, a decanoyl group, an undecanoyl group, a dodecanoyl group, a hexadecanoyl group, an octadecanoyl group, and an isostearyl group
- R 2 is a hydrogen atom.
- X 1 to X 3 each independently represent a nitrogen or oxygen atom
- R 3 , R 4 , R 5 , R 3 ′ , R 4 ′ , R 5 ′ are each Independently represents a hydrogen atom or a chain hydrocarbon group having 1 to 30 carbon atoms which may have a branched or unsaturated bond (provided that X 1 , X 2 and X 3 are each an oxygen atom, , There is no corresponding R 3 ′ , R 4 ′ , R 5 ′ ).
- —CONR m R m ′ (m and m ′ represent the same number of 3, 4, and 5 corresponding to X 1 to X 3 ) Represents a substituted or unsubstituted amide group
- —COOR m (m is any one of 3, 4, and 5 corresponding to X 1 to X 3 Represents a carboxyl group or an ester group.
- R 3 , R 4 , R 5 , R 3 ′ , R 4 ′ , and R 5 ′ are each independently a hydrogen atom or 1 to 30 carbon atoms, preferably 8 provided that the above proviso is satisfied.
- sugar residues derived from monosaccharides and polysaccharides may be used.
- R 3 , R 4 , R 5 , R 3 ′ , R 4 ′ and R 5 ′ are each independently a hydrogen atom, methyl group, ethyl group, propyl group, isopropyl group, butyl Group, 1-methylpropyl group, 2-methylpropyl group, pentyl group, 1-methylbutyl group, 2-methylbutyl group, 3-methylbutyl group, 1-ethylpropyl group, hexyl group, 1-methylpentyl group, 2-methyl Pentyl group, 3-methylpentyl group, 4-methylpentyl group, 1-ethylbutyl group, 2-ethylbutyl group, heptyl group, 1-methylhexyl group, 2-methylhexyl group, 3-methylhexyl group, 4-methylhexyl Group, 5-methylhexyl group, 1-ethylpentyl group, 2-ethylpentyl group, 3-ethylpent
- R 3 , R 4 , R 5 , R 3 ′ , R 4 ′ , and R 5 ′ are each independently a hydrogen atom, a methyl group, provided that the above proviso is satisfied.
- the aspect which is is mentioned.
- More preferred examples include one or two of R 3 , R 4 , R 5 , R 3 ′ , R 4 ′ , and R 5 ′, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, and a hexyl group.
- X 1 to X 3 are each independently a nitrogen atom or an oxygen atom, but all may be the same atom or a mixture thereof. Preferred examples are the same atom, and a more preferred example is an oxygen atom.
- the modified carboxyl group moiety is —COOR m (m is any number of 3, 4, and 5 corresponding to X 1 to X 3. Represents a carboxyl group or an ester group. In this case, R 3 ′ , R 4 ′ and R 5 ′ do not exist.
- the hydroxycitrate derivative according to the mitochondrial function improving agent of the present invention includes a compound in which at least one of the hydroxyl groups at the 2-position or 3-position of hydroxycitric acid is modified, and a compound in which at least one of the carboxyl groups of the compound is further modified Are preferred.
- at least one of the carboxyl group sites of the derivative in which the hydroxyl group in the molecule has already been modified is a substituted or unsubstituted amide group or an ester group. The compound which has become.
- the hydroxycitrate derivative according to the mitochondrial function improving agent of the present invention includes a compound in which at least one of the hydroxyl groups is modified and the carboxyl group is not modified as described above, and the hydroxyl group as described above.
- Examples include compounds in which at least one and at least one of the carboxyl groups are modified together. Specific examples of these compounds include compounds combining the above examples of R 1 , R 2 , X 1 to X 3 , R 3 , R 4 , R 5 , R 3 ′ , R 4 ′ , and R 5 ′. Preferably mentioned.
- R 2 is a hydrogen atom
- R 3 to R 5 are all hydrogen atoms
- R 1 is represented by the above formula (Ia). It represents any group selected from the group shown, and among the groups represented by the above formula (Ia), the group represented by the above formula (Ia-1) is preferable.
- R 6 is preferably a chain hydrocarbon group having 7 to 23 carbon atoms which may have a branch, an unsaturated bond or a substituent, and has 10 to 22 carbon atoms.
- the chain hydrocarbon group is preferably a chain saturated hydrocarbon group, more preferably a chain hydrocarbon group having 13 to 21 carbon atoms, and still more preferably a chain hydrocarbon group having 13 to 18 carbon atoms.
- the chain hydrocarbon group is preferably a chain saturated hydrocarbon group, and more preferably has no substituent.
- R 6 is preferably a chain saturated hydrocarbon group having 7 to 23 carbon atoms having no substituent, and is preferably a chain saturated hydrocarbon group having 10 to 22 carbon atoms having no substituent.
- a chain saturated hydrocarbon group having 13 to 21 carbon atoms that has no substituent is more preferable, and a chain saturated hydrocarbon group having 13 to 18 carbon atoms that has no substituent is more preferable. preferable.
- the chain hydrocarbon group is preferably a linear saturated hydrocarbon group, and more preferably has no substituent.
- R 6 is preferably a straight-chain saturated hydrocarbon group having 7 to 23 carbon atoms having no substituent, and a straight-chain saturated hydrocarbon group having 10 to 22 carbon atoms having no substituent. More preferably, it is a straight chain saturated hydrocarbon group having 13 to 21 carbon atoms having no substituent, and a straight chain saturated hydrocarbon group having 13 to 18 carbon atoms having no substituent. More preferably it is.
- R 1 is preferably an acyl group having 14 to 22 carbon atoms.
- hydroxycitrate derivative according to the mitochondrial function improving agent of the present invention include hydroxycitrate-2-octanoate, hydroxycitrate-2-caprate, hydroxycitrate-2-laurate, hydroxycitrate-2-milli State, hydroxycitric acid-2-palmitate, hydroxycitric acid-2-stearate, hydroxycitric acid-2-behenoate, hydroxycitric acid-2-isopalmitate, hydroxycitric acid-2-isostearate, hydroxycitric acid-2 -Hexyldecanoate, hydroxycitric acid-2-linoleate, hydroxycitric acid monomethyl ester-2-myristate, hydroxycitric acid monomethyl ester-2-palmitate, hydroxycitric acid monomethyl ester-2- Teareto and the like.
- preferred examples include hydroxycitric acid-2-laurate, hydroxycitric acid-2-myristate, hydroxycitric acid-2-palmitate, hydroxycitric acid-2-stearate, hydroxycitric acid-2-behenoate Hydroxycitric acid-2-isopalmitate, hydroxycitric acid-2-isostearate, hydroxycitric acid-2-hexyldecanoate, hydroxycitric acid-2-linoleate.
- hydroxycitric acid-2-myristate hydroxycitric acid-2-palmitate
- hydroxycitric acid-2-stearate hydroxycitric acid-2-stearate
- Examples of the salt of the hydroxycitrate derivative according to the mitochondrial function improving agent of the present invention include alkali metal salts and alkaline earth metal salts of the hydroxycitrate derivative.
- Examples of the alkali metal salt include sodium salt and potassium salt, and examples of the alkaline earth metal salt include calcium salt.
- the mitochondrial function improving agent of the present invention has an effect of improving intracellular mitochondrial function. This is considered to be because the mitochondrial function improving agent of the present invention suppresses apoptosis induced by mitochondrial function decline.
- a method for administering the hydroxycitrate derivative or a salt thereof according to the mitochondrial function improving agent of the present invention methods known to those skilled in the art such as oral administration, intraarterial injection, intravenous injection and the like can be selected.
- administering the hydroxycitrate derivative or a salt thereof according to the mitochondrial function improving agent of the present invention to cultured cells or the like it can be used by adding to the culture medium of the cultured cells.
- the dose of the hydroxycitric acid derivative or a salt thereof may be determined by the blood concentration or the culture solution concentration of the hydroxycitrate derivative or a salt thereof.
- the blood concentration or the culture solution concentration (molar ratio) of the hydroxycitrate derivative or salt thereof is preferably about 0.001 ⁇ M to 100 ⁇ M, for example, about 0.005 ⁇ M to 50 ⁇ M. More preferably, it is more preferably about 0.005 ⁇ M to 20 ⁇ M.
- the present invention provides a method for improving mitochondrial function comprising contacting an effective amount of a hydroxycitrate derivative or a salt thereof with a cultured cell.
- the present invention provides a hydroxycitrate derivative or a salt thereof for the prevention or treatment of a disease associated with hypomitochondrial function.
- the present invention provides the use of a hydroxycitrate derivative or a salt thereof for the prevention or treatment of a disease associated with reduced mitochondrial function.
- the present invention provides the use of a hydroxycitrate derivative or a salt thereof for the manufacture of a prophylactic or therapeutic agent for a disease associated with reduced mitochondrial function.
- the present invention provides a method for preventing or treating a disease associated with hypomitochondrial function, comprising administering an effective amount of a hydroxycitrate derivative or a salt thereof to a patient in need of treatment.
- Examples of diseases associated with reduced mitochondrial function include mitochondrial abnormalities and mitochondrial diseases.
- Improvement of mitochondrial function can be confirmed by measuring cells that have undergone apoptosis using the method described in Examples below, using the mitochondrial membrane potential as an index. For example, comparing a cell group contacted with a mitochondrial function improving agent with a cell group not contacted with a mitochondrial function improving agent, the cell group contacted with the mitochondrial function improving agent indicates the mitochondrial membrane potential. When the percentage of cells having undergone apoptosis obtained as described above is low, it can be determined that the mitochondrial function improving agent has an effect of improving mitochondrial function.
- the mitochondrial function improving agent may be provided as a derivative of hydroxycitric acid or a salt thereof, or may be provided as a composition mixed with an appropriate additive.
- additives oily bases, moisturizers, feel improvers, surfactants, polymers, thickeners / gelling agents, solvents, propellants, antioxidants, reducing agents, oxidizing agents, preservatives, described later,
- the method for producing the hydroxycitrate derivative or its salt according to the mitochondrial function improving agent of the present invention is not particularly limited, and hydroxycitric acid and / or its alkali metal salt and / or its alkaline earth metal salt and carboxylic acid derivative Alternatively, it can be produced by reacting a phosphoric acid derivative or a sulfonic acid derivative in an appropriate solvent.
- hydroxycitric acid For example, using commercially available hydroxycitric acid as a raw material, (1) A method of directly esterifying a hydroxyl group of hydroxycitric acid, (2) A method of esterifying the carboxyl group of hydroxycitric acid, then esterifying the hydroxyl group, cleaving the former ester bond site and returning it to the carboxyl group, (3) A method of esterifying a hydroxyl group after esterifying the carboxyl group of hydroxycitric acid, (4) a method of esterifying a hydroxyl group of hydroxycitric acid and then esterifying a carboxyl group, (5) A method of esterifying a hydroxyl group after amidating the carboxyl group of hydroxycitric acid, (6) A method of amidating the carboxyl group of hydroxycitric acid, then esterifying the hydroxyl group, cleaving the former amide bond site and returning it to the carboxyl group, (7) A method of esterifying the hydroxyl group
- R 1 is an acyl group having 14 to 22 carbon atoms
- R 2 is a hydrogen atom
- R 3 to R 5 are all preferable compounds among the compounds related to the mitochondrial function improving agent of the present invention.
- the method for producing the compound represented by the formula (IIa) which is a hydrogen atom and X 1 to X 3 are all oxygen atoms For example, it can be produced by the method (1) or (2) using commercially available hydroxycitric acid as a raw material.
- the ester of hydroxycitric acid is obtained by esterifying hydroxycitric acid (or its alkali metal salt or alkaline earth metal salt) according to a conventional method. More specifically, for example, for long-chain acylhydroxycitric acid, a corresponding long-chain carboxylic acid and hydroxycitric acid (which may be an alkali metal salt or alkaline earth metal salt of hydroxycitric acid) and a suitable solvent It can be produced by reacting under a catalyst (for example, Tetrahedron Letters, 1970, page 4011).
- hydroxycitric acid which may be an alkali metal salt or an alkaline earth metal salt of hydroxycitric acid
- an appropriate solvent environment see, for example, Chem. Rev., 52, 239, 1953.
- carboxylic acid anhydride and hydroxycitric acid which may be an alkali metal salt or an alkaline earth metal salt of hydroxycitric acid
- esterifying agents capable of activating the corresponding long-chain carboxylic acid and hydroxycitric acid which may be an alkali metal salt or alkaline earth metal salt of hydroxycitric acid
- organic Synthesis, 63, 183 for example, organic Synthesis, 63, 183
- corresponding long-chain alkyl nitrile and hydroxycitric acid which may be an alkali metal salt or alkaline earth metal salt of hydroxycitric acid
- hydroxycitric acid which may be an alkali metal salt or alkaline earth metal salt of hydroxycitric acid
- alcohol for example, Benzyl alcohol
- the first step of protecting the tricarboxylic acid site of hydroxycitric acid for example, protecting with benzyl ester
- the alcohol used in the first step is not particularly limited as long as it can selectively protect and deprotect only the carboxyl group site of hydroxycitric acid.
- benzyl alcohol, substituted benzyl alcohol, tert-butanol 2,2,2-trichloroethanol and the like are preferred.
- benzyl alcohol and substituted benzyl alcohol are preferred.
- it when protected with benzyl ester in the first step, it can be deprotected by a reaction such as catalytic reduction in the third step.
- R 1 is an acyl group having 14 to 22 carbon atoms
- R 2 is a hydrogen atom
- R 3 to R 5 are each independently preferred compounds among the compounds related to the mitochondrial function improving agent of the present invention.
- the method for producing the compound represented by the formula (IIb) wherein X 1 to X 3 are all oxygen atoms For example, it can be produced by the methods (2) to (4) above using commercially available hydroxycitric acid as a raw material.
- the method for producing a derivative or salt of hydroxycitric acid according to the mitochondrial function improving agent may include other steps between the above three steps.
- a step such as distillation, extraction, and crystallization for separating and purifying the product between the first step and the second step, and between the second step and the third step.
- the solvent used is not particularly limited as long as it dissolves or suspends these starting materials.
- DMF dimethyl sulfoxide, trisdimethylaminophosphine, and water are preferable. These solvents may be used alone or in combination of two or more.
- the solvent used is not particularly limited as long as it dissolves or suspends these starting materials, but tetrahydrofuran (hereinafter sometimes referred to as “THF”). , Chloroform, dichloromethane, dioxane and the like are preferable. These solvents may be used alone or in combination of two or more.
- the reaction temperature is not particularly limited as long as it is not higher than the boiling point of the solvent used. Specifically, for example, a range of ⁇ 20 ° C. to 100 ° C. is preferable, and a range of 0 ° C. to 60 ° C. is more preferable.
- the reaction concentration is not particularly limited, preferably in the range of 0.0001mol / dm 3 ⁇ 10mol / dm 3, more preferably in the range of 0.1mol / dm 3 ⁇ 1mol / dm 3.
- the reaction system is preferably alkaline.
- the salt of a hydroxy citrate derivative can be easily manufactured by performing such pH adjustment.
- NaOH is used as a pH adjuster, a Na salt of a hydroxycitric acid derivative can be obtained.
- the agent for improving mitochondrial function of the present invention comprises a derivative of hydroxycitric acid or a salt thereof, hydroxycitrate and / or an alkali metal salt thereof and / or an alkaline earth metal salt thereof, a carboxylic acid derivative or phosphorus It may be produced by reacting an acid derivative or a sulfonic acid derivative in a solvent.
- the agent for improving mitochondrial function of the present invention is a derivative of hydroxycitric acid or a salt thereof obtained by reacting hydroxycitric acid and / or an alkali metal salt thereof and / or an alkaline earth metal salt thereof with an alcohol in a solvent.
- a hydroxycitrate derivative having a third step of cleaving a part or all of the ester bond site formed in the first step among the ester bond sites of the compound obtained in the second step; It may be produced by a method for producing the salt.
- the anti-aging composition of the present invention is An anti-aging composition comprising a hydroxycitric acid derivative represented by the following formula (I) or a salt thereof as an active ingredient;
- R 1 and R 2 each independently represent a hydrogen atom or any group selected from the group represented by the following formula (Ia) (provided that R 1 and R 2 are simultaneously X 1 to X 3 each independently represent a nitrogen or oxygen atom, and R 3 , R 4 , R 5 , R 3 ′ , R 4 ′ , and R 5 ′ represent each Independently represents a hydrogen atom, or a chain hydrocarbon group having 1 to 30 carbon atoms which may have a branched or unsaturated bond (provided that X 1 , X 2 and X 3 are each an oxygen atom, , There is no corresponding R 3 ′ , R 4 ′ , R 5 ′ ).
- R 6 to R 8 are each independently a hydrogen atom, an aryl group, or a chain hydrocarbon group having 1 to 30 carbon atoms, which may have a branched, unsaturated bond or substituent. Represents.
- the derivative of hydroxycitric acid or a salt thereof is the same as that exemplified for the mitochondrial function-improving agent, and the description thereof is omitted.
- the anti-aging composition of the present invention contains the mitochondrial function-improving agent as an active ingredient. You may do.
- the anti-aging composition of the present invention may be provided as a derivative of hydroxycitric acid or a salt thereof, and, if necessary, a component usually used for a skin external preparation within a range not impairing the effects of the present invention.
- a component usually used for a skin external preparation within a range not impairing the effects of the present invention.
- it may contain a pharmaceutically acceptable carrier, additive or the like as an external preparation for skin.
- examples of such components include oily bases, moisturizers, feel improvers, surfactants, polymers, thickening / gelling agents, solvents, propellants, antioxidants, reducing agents, oxidizing agents, preservatives.
- Agent antibacterial agent, chelating agent, pH adjuster, acid, alkali, powder, inorganic salt, ultraviolet absorber, whitening agent, vitamins and derivatives thereof, anti-inflammatory agent, anti-inflammatory agent, hair growth agent, blood circulation promoter , Stimulants, hormones, anti-wrinkle agents, anti-aging agents, squeeze agents, cooling sensation agents, warming sensation agents, wound healing promoters, stimulation mitigation agents, analgesics, cell activators, plant / animal / microbe extracts, antipruritic agents Agent, exfoliating / dissolving agent, antiperspirant, refreshing agent, astringent, enzyme, nucleic acid, fragrance, pigment, colorant, dye, pigment, water, metal-containing compound, unsaturated monomer, polyhydric alcohol, high Molecular additive, anti-inflammatory analgesic, antifungal, antihistamine, hypnotic sedative, tranquilizer, anti Blood pressure agent, antihypertensive diuretic, antibiotic, anesthetic agent, antibacterial agent, antiepileptic
- oily bases examples include cetanol, myristyl alcohol, oleyl alcohol, lauryl alcohol, cetostearyl alcohol, stearyl alcohol, aralkyl alcohol, behenyl alcohol, jojoba alcohol, chimyl alcohol, ceralkyl alcohol, batyl alcohol, hexyldecanol, and isostearyl.
- Higher alcohols such as alcohol, 2-octyldodecanol and dimer diol; aralkyl alcohols and derivatives such as benzyl alcohol; lauric acid, myristic acid, palmitic acid, stearic acid, isostearic acid, behenic acid, undecylenic acid, 12-hydroxystearic acid Acid, palmitooleic acid, oleic acid, linoleic acid, linolenic acid, erucic acid, docosahexaenoic acid, eicosapentaenoic acid, Higher fatty acids such as sohexadecanoic acid, anteisohenicosanoic acid, long-chain branched fatty acid, dimer acid, hydrogenated dimer acid, and metal soaps such as aluminum salts, calcium salts, magnesium salts, zinc salts, potassium salts, And nitrogen-containing derivatives such as amides; liquid paraffin (mineral oil), heavy liquid isoparaffin, light
- Lipid complex Lipid complex; octyldodecyl myristate, hexyldecyl myristate, octyldodecyl isostearate, cetyl parmitate, octyldodecyl palmitate, cetyl octanoate, hexyl decyl octanoate, isotridecyl isononanoate, isononyl isononanoate, isononanoate Isotridecyl acid, isodecyl neopentanoate, isotridecyl neopentanoate, isostearyl neopentanoate, octyl neodecanoate Dodecyl, oleyl oleate, octyldodecyl oleate, octyldodecyl ricino
- humectant / feel improver examples include polyhydric alcohols such as glycerin, propylene glycol, 1,3-butylene glycol, sorbitol, polyglycerin, polyethylene glycol, and dipropylene glycol; NMF components such as sodium lactate, hyaluronic acid Water-soluble polymers such as collagen, mucopolysaccharide, chondroitin sulfate; glycerin, 1,3-butylene glycol, propylene glycol, 3-methyl-1,3-butanediol, 1,3-propanediol, 2-methyl- 1,3-propanediol, trimethylolpropane, pentaerythritol, hexylene glycol, diglycerin, polyglycerin, diethylene glycol, polyethylene glycol, dipropylene glycol, polypropylene glycol, ethylene Polyols such as recall / propylene glycol copolymer and polymers
- surfactant examples include lauryl sulfate ester salt, polyoxyethylene alkyl ether sulfate, alkyl benzene sulfonate, polyoxyethylene alkyl ether phosphate, polyoxyethylene alkyl phenyl ether phosphate, N-acyl amino acid salt, stearin Anionic surfactants such as sodium acid, potassium palmitate, sodium cetyl sulfate, sodium lauryl sulfate, triethanolamine palmitate, sodium polyoxyethylene lauryl phosphate, sodium acylglutamate, surfactin; benzalkonium chloride, benzethonium chloride, Cationic surfactants such as stearyltrimethylammonium chloride, distearyldimethylammonium chloride, stearyldimethylbenzylammonium chloride; Amphoteric surfactants such as killiaminoethylglycine, 2-alkyl-N-carboxymethyl-N-hydroxye
- Imidazoline-type betaines alkylsulfobetaines such as alkyldimethyltaurine; sulfate-type betaines such as alkyldimethylaminoethanol sulfate; phosphate-type betaines such as alkyldimethylaminoethanol phosphate; phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, sphingomyelin Sphingophospholipids, lysolecithin, hydrogenated soybean phospholipid, partially hydrogenated soybean phospholipid, hydrogenated egg yolk phospholipid, partially hydrogenated egg yolk Phospholipids such as lipids and hydroxylated lecithin; amphoteric surfactants such as silicone-based amphoteric surfactants; polyvinyl alcohol, sodium alginate, starch derivatives, tragacanth gum, acrylic acid / methacrylic acid alkyl copolymers; Examples thereof include polymer surfactants such as surfactants
- polymer / thickening / gelling agent examples include guar gum, locust bean gum, queen's seed, carrageenan, galactan, gum arabic, tara gum, tamarind, far cerulean, caraya gum, troarooi, cara gum, tragacanth gum, pectin, pectic acid and Salt such as sodium salt, salt such as alginic acid and sodium salt, mannan; starch such as rice, corn, potato, wheat; xanthan gum, dextran, succinoglucan, curdlan, hyaluronic acid and its salt, xanthan gum, pullulan, gellan gum , Chitin, chitosan, agar, gypsum extract, chondroitin sulfate, casein, collagen, gelatin, albumin; methylcellulose, ethylcellulose, hydroxyethylcellulose, hydro Cypropylcellulose, carboxymethylcellulose and its salts such as sodium, methylhydroxypropy
- solvent / propellant examples include monohydric alcohols such as methanol, ethanol, propanol, benzyl alcohol, phenethyl alcohol, isopropyl alcohol, isobutyl alcohol, hexyl alcohol, 2-ethylhexanol, cyclohexanol, octyl alcohol, butanol, and pentanol.
- monohydric alcohols such as methanol, ethanol, propanol, benzyl alcohol, phenethyl alcohol, isopropyl alcohol, isobutyl alcohol, hexyl alcohol, 2-ethylhexanol, cyclohexanol, octyl alcohol, butanol, and pentanol.
- Ketones such as acetone and methyl ethyl ketone; lower alcohols such as ethanol, 2-propanol (isopropyl alcohol), butanol, and isobutyl alcohol; propylene glycol, 1,3-butylene glycol, diethylene glycol, dipropylene glycol, isopentyl diol, and the like;
- Glycols Diethylene glycol monoethyl ether (ethoxydiglycol), ethylene glycol monoethyl -Glycols such as ether, ethylene glycol monobutyl ether, triethylene glycol monoethyl ether, diethylene glycol diethyl ether, diethylene glycol dibutyl ether, propylene glycol monoethyl ether, dipropylene glycol monoethyl ether; ethylene glycol monoethyl ether acetate, diethylene glycol monoethyl Glycol ether esters such as ether acetate and propylene glyco
- antioxidant / reducing agent / oxidant examples include tocopherol derivatives such as tocopherol (vitamin E) and tocopherol acetate; BHT, BHA; gallic acid derivatives such as propyl gallate; vitamin C (ascorbic acid) and / or its Derivatives; erythorbic acid and derivatives thereof; sulfites such as sodium sulfite; bisulfites such as sodium bisulfite; thiosulfates such as sodium thiosulfate; metabisulfites; thiotaurine, hypotaurine; thioglycerol, thiourea, thioglycol Acid, cysteine hydrochloride, thioglycolic acid, cysteine, cysteamine; hydrogen peroxide solution, ammonium persulfate, sodium bromate, percarbonate, nordihydroguaiaretic acid, guaiac fat, butylhydroxyanisole, dibutylhydroxytol
- antiseptic / antibacterial agent / chelating agent examples include hydroxybenzoic acid such as methylparaben, ethylparaben, propylparaben, and butylparaben and salts or esters thereof; salicylic acid; sodium benzoate; phenoxyethanol; 1,2-pentanediol, 1,2-diols such as 1,2-hexanediol; isothiazoline derivatives such as methylchloroisothiazolinone and methylisothiazolinone; imidazolinium urea; dehydroacetic acid and its salts; phenols; halogenated bisphenols such as triclosan , Acid amides, quaternary ammonium salts; trichlorocarbanilide, zinc pyrithione, benzalkonium chloride, benzethonium chloride, sorbic acid, chlorhexidine, chlorhexidine gluconate, halocarban Hex
- Examples of the pH adjuster / acid / alkali include sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, 2-amino-2-methyl-1,3-propanediol, and 2-amino-2-hydroxy.
- Alkali metal hydroxides such as dipotassium hydrogen phosphate, monoethanolamine, diethanolamine, isopropanolamine, diisopropanolamine, polyethanolamine, alkaline earth metal hydroxides, primary and secondary Is a tertiary alkylamine or an alkali such as a primary, secondary or tertiary alkan
- the powder / inorganic salt examples include mica, talc, kaolin, sericite, montmorillonite, kaolinite, mica, muscovite, phlogopite, synthetic mica, red mica, biotite, permiculite, magnesium carbonate, calcium carbonate, silica Aluminum oxide, barium silicate, calcium silicate, magnesium silicate, strontium silicate, metal tungstate, magnesium, zeolite, barium sulfate, calcined calcium sulfate, calcium phosphate, fluorine apatite, hydroxyapatite, ceramic powder, bentonite, smectite, Clay, mud, metal soap (e.g.
- Inorganic brown pigments inorganic yellow pigments such as yellow iron oxide and ocher, inorganic black pigments such as black iron oxide and carbon black, inorganic purple pigments such as manganese violet and cobalt violet, chromium hydroxide, chromium oxide, cobalt oxide, Inorganic green pigments such as cobalt titanate, inorganic blue pigments such as bitumen and ultramarine blue, tar dyes raked, natural dyes raked, and composite powders obtained by combining these powders; Titanium oxide coated mica, titanium oxide coated mica, bismuth oxychloride, titanium oxide coated bismuth oxychloride, titanium oxide coated talc, fish scale foil, Pearl pigments such as titanium mica coated colored mica; metal powder pigments such as aluminum powder, copper powder, stainless steel powder; red 3, red 104, red 106, red 201, red 202, red 204, red 205 No., Red No.
- tar pigments such as No. Orange 207
- natural pigments such as carminic acid, laccaic acid, calsamine, bradylin, crocin, etc.
- ultraviolet absorber examples include paraaminobenzoic acid, paraaminobenzoic acid monoglycerin ester, N, N-dipropoxyparaaminobenzoic acid ethyl ester, N, N-diethoxyparaaminobenzoic acid ethyl ester, N, N-dimethylparaaminobenzoic acid.
- Benzoic acid ultraviolet absorbers such as ethyl acetate, N, N-dimethylparaaminobenzoic acid butyl ester and N, N-dimethylparaaminobenzoic acid ethyl ester; anthranilic acid ultraviolet absorbers such as homomenthyl-N-acetylanthranilate Salicylic acid and its sodium salt, amyl salicylate, menthyl salicylate, homomenthyl salicylate, octyl salicylate, phenyl salicylate, benzyl salicylate, p-isopropanol phenyl salicylate, etc.
- anthranilic acid ultraviolet absorbers such as homomenthyl-N-acetylanthranilate Salicylic acid and its sodium salt, amyl salicylate, menthyl salicylate, homomenthyl salicylate, octyl salicylate, phenyl salicylate, benzyl salicy
- Luric acid UV absorbers octyl cinnamate, ethyl-4-isopropyl cinnamate, methyl-2,5-diisopropyl cinnamate, ethyl-2,4-diisopropyl cinnamate, methyl-2,4-diisopropyl cinnamate, propyl -P-methoxycinnamate, isopropyl-p-methoxycinnamate, isoamyl-p-methoxycinnamate, 2-ethylhexyl p-methoxycinnamate (octyl paramethoxycinnamate), 2-ethoxyethyl-p-methoxycinnamate ( Synoxate), cyclohexyl-p-methoxycinnamate, ethyl- ⁇ -cyano- ⁇ -phenylcinnamate, 2-ethylhexyl ⁇ -cyano-
- Enon UV absorbers 3- (4'-methylbenzylidene) -d, l-camphor, 3-benzylidene-d, l-camphor; 2-phenyl-5-methylbenzoxazole; 2,2'-hydroxy- 2- (2′-hydroxy-5′-t-octylphenyl) benzotriazole; 2- (2′-hydroxy-5′-methylphenylbenzotriazole; dibenzalazine; dianisoylmethane; 5- (3,3-dimethyl-2-norbornylidene) -3-pentan-2-one; dibenzoylmethane derivatives such as 4-t-butylmethoxydibenzoylmethane; octyl triazone; urocanic acid such as urocanic acid and ethyl urocanate Derivatives; 2- (2′-hydroxy-5′-methylphenyl) benzotriazo 1, hydantoin derivatives such as 1- (3,4-dime
- whitening agents include hydroquinone glycosides such as arbutin and ⁇ -arbutin and esters thereof; ascorbic acid phosphates such as ascorbic acid, ascorbic acid phosphate sodium salt, and ascorbic acid phosphate magnesium salt; Ascorbic acid fatty acid ester such as ascorbic acid tetraisopalmitate, ascorbic acid alkyl ether such as ascorbic acid ethyl ether, ascorbic acid glucoside such as ascorbic acid-2-glucoside and its fatty acid esters, ascorbic acid sulfate, phosphoric acid toco Ascorbic acid derivatives such as ferryl ascorbyl; kojic acid, ellagic acid, tranexamic acid and its derivatives, ferulic acid and its derivatives, placenta extract, glutathione, oryzanol, Chill resorcinol, oil-soluble chamomile extract, oil-soluble licorice extract, Nishikawayanagi
- Vitamins and derivatives thereof include, for example, vitamin A such as retinol, retinol acetate, retinol palmitate; thiamine hydrochloride, thiamine sulfate, riboflavin, riboflavin acetate, riboflavin butyrate, pyridoxine hydrochloride, pyridoxine dioctanoate , Pyridoxine dipalmitate, flavin adenine dinucleotide, cyanocobalamin, folic acid, nicotinic acids such as nicotinic acid amide / benzyl nicotinate, vitamin B group such as choline; vitamin C such as ascorbic acid and its sodium salt Vitamin D; vitamin E such as ⁇ , ⁇ , ⁇ , ⁇ -tocopherol; other vitamins such as pantothenic acid and biotin; sodium salt of ascorbic acid phosphate and magnesium salt of ascorbic acid phosphate Ascorbic acid phosphat
- Anti-inflammatory agent anti-inflammatory agent, hair growth agent, blood circulation promoter, stimulant, hormones, anti-wrinkle agent, anti-aging agent, squeeze agent, cooling sensation agent, warming sensation agent, wound healing promoter, stimulation relieving agent, analgesic
- agents and cell activators include, for example, glycyrrhizic acid and its derivatives, glycyrrhetinic acid derivatives, salicylic acid derivatives, hinokitiol, guaiazulene, allantoin, indomethacin, zinc oxide, hydrocortisone acetate, prednisone, diphedramine hydrochloride, chlorpheniramine maleate; Extracts, plant extracts such as bamboo leaf extract; plant extracts and tinctures such as assembly extract, capsicum tincture, ginger tincture, ginger extract, cantalis tincture, etc .; Cycelele , Cinnarizine, trazoline, acetylcholine, verapamil, ce
- plant / animal / microbe extracts examples include iris extract, ashitaba extract, asunalo extract, asparagus extract, avocado extract, achacha extract, almond extract,retea extract, arnica extract, aloe extract, apricot extract, apricot kernel extract, ginkgo biloba Extract, Inch extract, fennel extract, turmeric extract, oolong tea extract, walnut extract, ages extract, Echinacea leaf extract, entomop extract, Ogon extract, Oat extract, Auren extract, barley extract, ginseng extract, Hypericum extract, Odrianthus extract, Ononis extract, Dutch mustard extract, orange extract, dried seawater, seaweed extract, oyster leaf extract, oyster extract, hydrolyzed elastin, hydrolyzed wheat powder Hydrolyzed silk, coconut extract, chamomile extract, oil-soluble chamomile extract, carrot extract, kawara mugi extract, oat extract, calcade extract, licorice extract, oil-soluble licorice extract,
- nucleic acids such as diphenhydramine hydrochloride, chlorphen
- flavors include coconut oil, orange oil, pepper oil, jasmine oil, cedar oil, ginger oil, terpin oil, orange flower oil, rose oil, eucalyptus oil, lime oil, lemon oil, Japanese mint oil, rosemary.
- Vegetable fragrances such as oil; animal fragrances such as musk, reibiko, kairikou and rysenkou; hydrocarbon fragrances such as bromostyrol, pinene and limonene; alcohol fragrances such as benzyl alcohol and l-menthol; ethyl acetate and methyl salicylate Ester-based fragrances such as benzaldehyde and salicylaldehyde; aldehyde-based fragrances such as camphor, muscone, musk ketone, and l-menton; ether-based fragrances such as safrole; phenol-based fragrances such as thymol; Lactone-based fragrances; Acid-based fragrances such as phenylacetic acid; Indole
- Nitrogen compound fragrances acetyl cedrene, amylcinnamaldehyde, allyl amyl glycolate, ⁇ -ionone, iso-Esuper, isobutyl quinoline, Iris oil, Iron, ylang ylang oil, undecanal, undecenal, ⁇ -undecalactone, estra Gall, oak moss, oponax resininoid, eugenol, auranthiol, galac solid, carvacrol, L-carvone, cannon, carrot seed oil, clove oil, methyl cinnamate, geraniol, geranyl nitrile, isobornyl acetate, geranyl acetate, acetic acid Dimethylbenzyl carvinyl, styrylyl acetate, cedolyl acetate, terpinel acetate, pt-butylcyclohexyl acetate, vetiberyl
- pigments / colorants / dyes / pigments include brown 201, black 401, purple 201, purple 401, blue 1, blue 2, blue 201, blue 202, blue 203, blue 204, Blue 205, Blue 403, Blue 404, Green 201, Green 202, Green 204, Green 205, Green 3, Green 401, Green 402, Red 102, Red 104- No.
- Yellow No. 201 Yellow 202-1, Yellow 202-2, Yellow 203, Yellow 204, Yellow 205, Yellow 4, Yellow 401, Yellow 402, Yellow 403-1, Yellow 404, Yellow 405, Yellow Legal dyes such as No. 406, Yellow No. 407, Yellow No.
- Acid Red 14 Basic dyes such as Arianor Sienna Brown, Arianor Madder Red, Arianor Steel Blue, Arianor Straw Yellow
- HC Yellow 2 HC Yellow 5, H Nitro dyes such as CRed 3, 4-hydoxypropylamino-3-nitrophenol, N, N'-bis (2-hydroxyethyl) -2-nitro-p-phenylenediamine, HC Blue 2, Basic Blue 26; disperse dyes; titanium dioxide, oxidation Inorganic white pigments such as zinc; inorganic red pigments such as iron oxide (Bengara) and iron titanate; inorganic brown pigments such as ⁇ -iron oxide; inorganic yellow pigments such as yellow iron oxide and loess; black iron oxide; Inorganic black pigments such as low-order titanium oxide; inorganic purple pigments such as mango violet and cobalt violet; chromium oxide; Inorganic green pigments such as chromium hydroxide and cobalt titanate; inorgan
- Examples of water include normal water, purified water, hard water, soft water, natural water, deep sea water, electrolytic alkali ion water, electrolytic acid ion water, ion water, and cluster water.
- the metal-containing compound examples include lithium oxide, butyl lithium, ethyl lithium, lithium bromide, lithium carbide, lithium iodide, lithium nitrate, lithium nitride, lithium sulfide, methyl lithium, lithium sulfate, lithium chloride, lithium hydride, Propyl lithium, lithium carbonate, lithium fluoride, lithium niobate, lithium peroxide, lithium hydroxide, lithium molybdate, lithium perchlorate, lithium acetate, lithium formate, lithium tungstate, lithium hypochlorite, lithium acetate Hydrate, lithium iodide dihydrate, lithium hydrogen sulfate, lithium acetate dihydrate, lithium bromide monohydrate, lithium sulfate monohydrate, dilithium carbonate, dilithium oxalate, dilithium sulfate, Lithium chromate dihydrate, lithium hydroxide monohydrate, Lithium enoate tetrahydrate, lithium perchlorate trihydrate, lithium compounds such
- unsaturated monomers examples include acrylic acid polymers, maleic acid, maleic anhydride, fumaric acid, crotonic acid, itaconic acid, vinyl sulfonic acid, styrene sulfonic acid, 2- (meth) acrylamido-2-methyl.
- Hydrophilic unsaturated monomers containing acid groups such as propanesulfonic acid, 2- (meth) acryloylethanesulfonic acid, 2- (meth) acryloylpropanesulfonic acid, and salts thereof; N-vinylacetamide, N-methyl-N -Vinylacetamide, acrylamide, methacrylamide, N-ethyl (meth) acrylamide, Nn-propyl (meth) acrylamide, N-isopropyl (meth) acrylamide, N, N-dimethyl (meth) acrylamide, 2-hydroxyethyl ( (Meth) acrylate, 2-hydroxypropyl (meth) acrylate
- Nonionic hydrophilic unsaturated monomers such as acrylate, methoxypolyethylene glycol (meth) acrylate, polyethylene glycol mono (meth) acrylate, vinylpyridine, N-vinylpyrrolidone, N-acryloylpiperidine, N-acryl
- polyhydric alcohol examples include ethylene glycol, propylene glycol, 1,3-butylene glycol, ethylene glycol monobutyl ether, diethylene glycol, triethylene glycol, 1,4-butylene glycol (dihydric alcohol), glycerin, trioxyisobutane ( (Trihydric alcohol), erythritol, pentaerythritol (tetrahydric alcohol), xylite, adnit (pentahydric alcohol), allozulcit, sorbitol, sorbitol liquid, mannitol (hexahydric alcohol), polyglycerin, and dipropylene glycol.
- Trihydric alcohol Trihydric alcohol
- erythritol pentaerythritol (tetrahydric alcohol)
- xylite adnit (pentahydric alcohol)
- allozulcit sorbitol, sorbitol liquid, mannitol (
- polymer additive examples include N-vinylacetamide such as polyvinylpyrrolidone, carboxyvinyl polymer which is cross-linked polyacrylic acid, vinylpyrrolidone-ethyl acrylate copolymer, and N-vinylacetamide-sodium acrylate copolymer.
- copolymer examples include N-vinylacetamide homopolymer, polyvinylsulfonic acid, N-vinylacetamide cross-linked product, polyitaconic acid, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
- Anti-inflammatory analgesics include, for example, salicylic acid, glycol salicylate, methyl salicylate, 1-menthol, camphor, sulindac, trimethine sodium, naproxen, fenbufen, piroxicam, triamcinolone, hydrocortisone acetate, indomethacin, ketoprofen, acetaminophen, mefenamic acid, Flufenamic acid, ibufenac, loxoprofen, thiaprofen, pranoprofen, fenbufen, diclofenac, diclofenac sodium, alclofenac, lornoxicam, pranoprofen, oxyphenbutazone, ibuprofen, felbinac, ketrolac, vermoprofen, nabumetone, naproxen, flur Biprofen, fluocinonide, clobetasol propionate COX-2 inhibitors (celecoxi
- Antifungal agents include, for example, clotrimazole, econazole nitrate, omoconazole nitrate, thioconazole nitrate, ketoconazole nitrate, miconazole nitrate, isoconazole nitrate, tolnaftate, sulconazole nitrate, pyrrolnitrin, pimafucin, undecylenic acid, salicylic acid, siccanin, nystatin, Nonnaphthate, exalamide, phenyliodoundecinoate, thianthol, ciclopirox olamine, haloprozine, tricomycin, variotin, pentamycin, amphotericin B.
- antihistamine examples include antibiotics such as tetracycline hydrochloride, diphenhydramine hydrochloride, chlorpheniramine, diphenylimidazole, chloramphenicol, diphenhydramine, chlorpheniramine maleate, diphenhydramine hydrochloride, chlorpheniramine, and diphenylimidazole.
- antibiotics such as tetracycline hydrochloride, diphenhydramine hydrochloride, chlorpheniramine, diphenylimidazole, chloramphenicol, diphenhydramine, chlorpheniramine maleate, diphenhydramine hydrochloride, chlorpheniramine, and diphenylimidazole.
- hypothalamic sedative examples include phenobarbital, amobarbital, cyclobarbital, lorazepam, and haloperidol.
- Examples of the tranquilizer include fluphenazine, thioridazine, diazepam, flunitrazepam, and chlorpromazine.
- antihypertensive agent examples include clonidine, clinidine hydrochloride, pindolol, propranol, propranol hydrochloride, bufuranol, indenolol, bucmolol, and nifedipine.
- antihypertensive diuretics examples include hydrothiazide and cyclopenthiazide.
- antibiotics examples include penicillin, tetracycline, oxytetracycline, fradiomycin sulfate, erythromycin, and chloramphenicol.
- anesthetic examples include lidocaine, benzocaine, ethyl aminobenzoate, and dibucaine.
- antibacterial substances examples include benzalkonium chloride, nitrofurazone, nystatin, acetosulfamine, and clotrimazole.
- antiepileptic agents examples include nitrazepam, meprobamate, and clonazepam.
- coronary vasodilators include nitroglycerin, nitroglycol, isosorbidinitrate, erythritol tetranitrate, pentaerythritol tetranitrate, and propatyl nitrate.
- herbal medicines include, butterfly, spruce, onji, gadget, chamomile, caroten, licorice, kyoukyo, kyounin, gou, trash, saikachi, psycho, saishin, shiazenshi, shouma, senega, sojutsu, sohakuhi, choji, chimney, tokon, Nantenjitsu, Baimo, Bakumondou, Hange, Beakkujutsu, Hiyos, Bowfu, and Maou.
- adjuvants examples include ethyl alcohol, isopropyl alcohol, butanol, 1,3 butanediol, propylene glycol, polyethylene glycol # 400, glycerin, crotamiton, benzyl alcohol, phenylethyl alcohol, propylene carbonate, hexyl decanol, propanol, and salicylic acid.
- Terpene compounds and surfactants allantoin, dimethyl sulfoxide, dimethylacetamide, dimethylformamide, diisopropyl adipate, diethyl sebacate, Auxiliary agents such as chill laurate, lanolin, aison, etc., and other refreshing agents such as menthol and camphor, almond oil, olive oil, camellia oil, persic oil, peppermint oil, sesame oil, soybean oil, mink oil, cottonseed oil, corn Oil, safflower oil, coconut oil, eucalyptus oil, castor oil, liquid components such as liquid paraffin, petrolatum, squalene, squalane, lanolin, gelling agent such as carboxyvinyl polymer, and neutralizing agent such as diisopropanolamine .
- Auxiliary agents such as chill laurate, lanolin, aison, etc.
- other refreshing agents such as menthol and camphor, almond oil, olive oil, camellia oil,
- wetting agent examples include glycerin, propylene glycol, sorbit, 1,3-butylene glycol, dl-pyrrolidone carboxylic acid, and sodium lactate.
- astringents include citric acid, tartaric acid, lactic acid, aluminum chloride, aluminum sulfate, allantochlorohydroxyaluminum, allantoindihydroxyaluminum, aluminum phenolsulfonic acid, zinc paraphenolsulfonate, zinc sulfate, and aluminum chlorohydroxide. .
- thickeners examples include gum arabic, tragacanth gum, locust bean gum, guar gum, echo gum, karaya gum, agar, starch, carrageenan, alginic acid, alginates (eg sodium alginate), propylene glycol alginate, dextran, dextrin, amylose, gelatin , Collagen, pullulan, pectin, amylopectin, starch, amylopectin sodium semiglycolate, chitin, albumin, casein and other natural polymers, polyglutamic acid, polyaspartic acid, methylcellulose, ethylcellulose, propylcellulose, ethylmethylcellulose, hydroxyethylcellulose, hydroxy Propylcellulose, hydroxypropylmethylcellulose, carboxymethyl starch, Lucari metal carboxymethyl cellulose, alkali metal cellulose sulfate, cellulose graft polymer, crosslinked gelatin, cellulose acetate phthalate, starch
- tackifier examples include silicone rubber, polyisoprene rubber, styrene-block copolymer rubber, acrylic rubber, and natural rubber.
- antidiarrheal examples include camphor, thymol, menthol, polyoxyethylene lauryl ether, antihistamine, and ethyl aminobenzoate.
- keratin softening release agent examples include sulfur, thioxolone, selenium sulfide, salicylic acid, and resorcin.
- oily raw materials include almond oil, olive oil, hydrogenated oil, camellia oil, castor oil, owl oil, coconut oil, beeswax, whale wax, lanolin, carnauba wax, candelilla wax, liquid paraffin, petrolatum, microcrystalline wax, ceresin , Squalene, lauric acid, myristic acid, palmitic acid, stearic acid, isostearic acid, oleic acid, lauryl alcohol, cetanol, stearyl alcohol, oleyl alcohol, octyldodecanol, cholesterol, hexyldecanol, white sterol, cetyl lactate, isopropyl myristate, Hexyl laurate, myristyl myristate, isopropyl palmitate, octyldodecanol myristate, butyl stearate, cacao oil, tree wax, jojoba oil, Rape seed oil, avocado oil,
- UV blocking agent examples include benzophenone series such as ASL-24, Cyasorb UV-9, Uvinul M-40, benzoic acid series such as Salol, azole series such as Tinuvin P, nitrile series such as Uvinul N-35, Ancour, etc.
- Urea such as UA, Neo ⁇ HelipanpGive tan F, 2-amino-4-methoxybenzophenone, octyldimethylparaaminobenzoate, paraamino acids such as ethylhexylparamethoxycynamate, salicylic acid, benzofuran, coumarin, and azole Is mentioned.
- antiseptic disinfectants include acids such as benzoic acid, salicylic acid, dehydroacetic acid, sorbic acid, boric acid, and salts thereof, phenol, chlorocresol, chlorxylenol, isopropylmethylphenol, resorcin, orthophenylphenol, paraoxybenzoic acid ester , Phenols such as phenoxyethanol, thymol, hinokitiol, thioxolone, halogenated bisphenols such as hexachlorophene, 2,4,4'-trichloro-2'-hydroxydiphenyl ether, trichlorocarbanilide, halocarban, unicylenic acid monoethanolamide Amide compounds such as benzalkonium chloride, quaternary ammonium compounds such as alkylisoquinolinium bromide, benzethonium chloride, cetylpyridinium chloride, lauryldi Amphoteric surfactants such as aminoethyl
- Antioxidants include, for example, methyl L-ascorbate, ethyl L-ascorbate, propyl L-ascorbate, butyl L-ascorbate, pentyl L-ascorbate, L-ascorbic acid-2-palmitate, L-ascorbine Acid-2-isopalmitate, L-ascorbic acid-2-stearate, L-ascorbic acid-2-isostearate, L-ascorbic acid-6-palmitate, L-ascorbic acid-6 isopalmitate, L-ascorbic acid-6 Stearate, L-ascorbic acid-6-isostearate, L-ascorbic acid-2,6-dipalmitate, L-ascorbic acid-2,6-diisopalmitate, L-ascorbic acid-2,6-distearate L-ascorbic acid-2,6-diisostearate, Ascorbic acid-2-glucoside-6-palm
- liquid matrix examples include glycerin, polyhydric alcohol, ethanol, propanol, isopropanol, gelling agent, glycerin, methyl laurate, lauryl alcohol, glycerol monolaurate, oleic acid, oleyl alcohol, glycerol monooleate, glycerol dioleate And glycerol trioleate, nicotinic acid, 2-pyrazinecarboxylic acid, sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic acid), 2,5-dihydroxybenzoic acid, 5-methoxysalicylic acid, ⁇ -cyano-4 -Hydroxycinnamic acid, 3-hydroxypicolinic acid, diaminonaphthalene, 2- (4-hydroxyphenylazo) benzoic acid, disulanol, succinic acid, 5- (trifluoromethyl) uracil, propylene glycol Dipropylene glycol, polypropylene
- fat-soluble substance examples include ascorbic acid isopalmitic acid, ascorbic acid-2-phosphoric acid-6-palmitate, ascorbic acid-2-phosphate-6-isopalmitate, ascorbic acid tetrahexyldecanoic acid, ascorbic acid-6-palmitate.
- polymer carboxylate examples include acrylic resins such as polyacrylic acid, acrylic acid-acrylonitrile copolymer, potassium acrylate-acrylonitrile copolymer, vinyl acetate-acrylic acid ester copolymer, and acrylic acid-alkyl acrylate copolymer.
- acrylic resins such as polyacrylic acid, acrylic acid-acrylonitrile copolymer, potassium acrylate-acrylonitrile copolymer, vinyl acetate-acrylic acid ester copolymer, and acrylic acid-alkyl acrylate copolymer.
- acrylic resins such as polyacrylic acid, acrylic acid-acrylonitrile copolymer, potassium acrylate-acrylonitrile copolymer, vinyl acetate-acrylic acid ester copolymer, and acrylic acid-alkyl acrylate copolymer.
- styrene-acrylic acid copolymer styrene-methacrylic acid copolymer, styrene-methacrylic acid
- Styrene acrylic resin such as: styrene-maleic acid copolymer, styrene-maleic anhydride copolymer; vinyl naphthalene-acrylic acid copolymer, vinyl acetate Vinyl acetate resins such as tylene copolymers, vinyl acetate-fatty acid vinyl ethylene copolymers, vinyl acetate-maleic acid ester copolymers, vinyl oxalate-crotonic acid copolymers and vinyl acetate-acrylic acid copolymers; and any polyester or cellulose polymer salt Can be mentioned.
- additives include hydrocarbons, waxes, fatty acids, higher alcohols, ester oils, silicone oils, fluorine oils, ozokerite, squalane, squalene, ceresin, paraffin, paraffin wax, liquid paraffin, Hydrocarbons such as pristane, polyisobutylene, microcrystalline wax, petrolatum, beeswax, carnauba wax, candelilla wax, waxes such as whale wax, beef tallow, beef leg fat, beef bone fat, hard beef fat, hard oil, turtle oil, Animal oil such as pork fat, horse fat, mink oil, liver oil, egg yolk oil, lanolin, liquid lanolin, reduced lanolin, lanolin alcohol, hard lanolin, lanolin acetate, lanolin fatty acid isopropyl, phospholipid, phosphadylcholine, POE lanolin alcohol ether, POE Lanolin Alcohol Acetate Lanolin derivatives such as lanolin fatty acid polyethylene glycol, POE hydrogenated phosphat
- metal soap examples include 12-hydroxyaluminum stearate, zinc stearate, aluminum stearate, calcium stearate, magnesium stearate, zinc myristate, magnesium myristate, zinc cetyl phosphate, calcium cetyl phosphate, sodium cetyl phosphate, and lauric acid. Zinc acid, undecylenic acid zinc are mentioned.
- Examples of the anti-aging composition of the present invention include cosmetics, external preparations for skin, and pharmaceuticals.
- an existing cosmetic raw material can be added at a general concentration.
- Cosmetic Material Standards Second Edition Commentary, Japan Official Church Church, 1984 (Pharmaceutical Daily Report), Cosmetic Raw Material Standards Independent Component Standard, Ministry of Health and Welfare Pharmaceutical Affairs Bureau Supervision Division, 1993 (Pharmaceutical Daily Report), Cosmetic Ingredients Nonstandard Component Standards supplement, supervised by the Ministry of Health and Welfare Pharmacy Examination Division, 1993 (Pharmaceutical Daily), permission standards by cosmetic type, supervision by the Ministry of Health and Welfare Pharmacy Examination Division, 1993 (Pharmaceutical Daily), formulation standard by cosmetic variety, Ministry of Health and Welfare Pharmacy Examination Division All cosmetic raw materials described in the supervision, 1997 (Pharmaceutical Daily), cosmetic raw material dictionary, 1991 (Nikko Chemicals), etc. can be used.
- Examples of the anti-aging composition of the present invention include shampoo, oil shampoo, cream shampoo, conditioning shampoo, dandruff shampoo, hair color shampoo, rinse integrated shampoo, rinse, treatment, hair pack, hair foam, hair mousse, Hair spray, hair mist, hair wax, hair gel, water grease, set lotion, color lotion, hair tonic, hair liquid, pomade, tic, hair cream, hair blow, split hair coat, hair oil, permanent wave agent, straight permanent agent, oxidation Hair dye, hair bleach, hair color pretreatment, hair color after treatment, perm pretreatment, perm after treatment, hair manicure, hair growth
- Cosmetics for hair selected from: facial cleansers, cleansing foams, washing powders, facial cleansing powders, cleansing creams, cleansing milks, cleansing lotions, cleansing gels, cleansing oils, cleansing masks, lotions, flexible lotions, astringent lotions, for washing Lotion, multi-layer lotion, emulsion, emollient lotion, moisture lotion, milky lotion, nourishing lotion, nourishing milk, skin moisture, moisturizer emulsion, massage lotion
- the dosage form of the anti-aging composition of the present invention is not particularly limited as long as it is used in contact with the skin at the time of use, and is appropriately set depending on the application.
- oil-in-water (O / W) type water-in-oil (W / O) type
- emulsified type such as W / O / W type, O / W / O type
- emulsified polymer type oily, solid, liquid, kneaded , Stick, volatile oil, powder, jelly, gel, paste, cream, sheet, film, mist, spray, multilayer, foam, flake
- the pH of the anti-aging composition of the present invention is preferably 6 to 9, and more preferably 7 to 8.5. When the pH is within this range, the stability of the hydroxycitric acid derivative is good, and the formulation stability is also better.
- the pH is a value at about 25 ° C.
- the compounding amount of the hydroxycitric acid derivative or salt thereof contained in the anti-aging composition of the present invention is, for example, as a ratio (mass%) of the hydroxycitric acid derivative or salt thereof in the anti-aging composition. It is preferably about 01% by mass to 20% by mass, more preferably about 0.05% by mass to 10% by mass, and further preferably about 0.1% by mass to 5% by mass.
- the anti-aging composition of the present invention is considered to have an effect of cell activation or cell function improvement by an effect of improving intracellular mitochondrial function by a mitochondrial function improving agent. It is useful for preventing or improving skin aging.
- the present invention provides a method for preventing cell aging, comprising contacting an effective amount of a hydroxycitrate derivative or a salt thereof with a cultured cell.
- the present invention provides a hydroxycitric acid derivative or a salt thereof for preventing or improving skin aging.
- the present invention provides the use of a hydroxycitrate derivative or a salt thereof for the prevention or amelioration of skin aging.
- the present invention provides the use of a hydroxycitric acid derivative or a salt thereof for the manufacture of an anti-aging composition.
- the present invention provides a method for preventing or improving skin aging, comprising contacting an effective amount of a hydroxycitrate derivative or a salt thereof with the skin of a patient in need of treatment.
- Prevention or improvement of skin aging can be confirmed by the method described in Examples below, using the amount of elastin produced by cells as an index. For example, comparing a cell group in contact with the anti-aging composition with a cell group not in contact with the anti-aging composition, the cell group in contact with the anti-aging composition is more When the amount of elastin production is high, it can be determined that the anti-aging composition has an effect of preventing or improving skin aging.
- Prevention or improvement of skin aging can be confirmed by using the skin condition as an index by the method described in Examples below. For example, comparing the skin contacted with the anti-aging composition with the skin not contacted with the anti-aging composition, the skin contacted with the anti-aging composition has a moisture content of the skin. If any difference between high, high skin smoothness and high skin elasticity occurs, it can be determined that the anti-aging composition has an effect of preventing or improving skin aging.
- Example 1 The preparation containing the hydroxycitric acid derivative according to the present invention can be formulated as a prescription example according to the prescription shown in the following (Table 1). Formulation Example 1 Cream
- Example 2 Confirmation of Mitochondrial Function Improvement Effect Mitochondrial function improvement effect in human skin-derived fibroblast NB1-RGB cells was measured under the following conditions using mitochondrial membrane potential as an index.
- Conjugated NB1-RGB cells are artificially oxidatively aged by culturing for 4 days in a DMME medium containing 10% fetal bovine serum containing 600 ⁇ M hydrogen peroxide solution for 4 days. Induced cells were designated as senescent cells. The senescent cells and untreated normal cells were prepared at a seeding density of 4000 cells / cm 2 and cultured in DMEM medium containing 10% fetal bovine serum for 24 hours.
- the fluorescent substance 5,5 ′, 6,6′-tetrachloro-1,1, ′, 3,3′-tetraethylbenzimidazolidocarboidine iodide (JC-1) is incorporated more into the mitochondria as the membrane potential is higher, and the red fluorescence in living cells When the membrane potential is low, it is not taken up by mitochondria and emits green fluorescence in apoptotic dead cells.
- JC-1 Mitochondrial Membrane Potential Assay Kit provided by Cayman
- JC-1 was added to the medium at a concentration of 10%, cultured for 15 minutes, and then centrifuged at 400 g for 5 minutes. Furthermore, after replacing the medium with the assay solution attached to the kit, centrifugation at 400 g for 5 minutes was repeated twice. After replacement with a new assay solution attached to the kit, the fluorescence intensity of live cells was measured at excitation 520 to 570 nm / fluorescence 570 to 610 nm, and the fluorescence intensity of dead cells was measured at excitation 485 nm / fluorescence 535 nm.
- Table 2 is a table showing relative values with the measured value for normal cells as 1, where only the green fluorescence intensity of the cell population to be measured is measured to determine the proportion of dead cells that have undergone apoptosis. is there.
- Table 2 the addition of the hydroxycitrate derivative according to the present invention shown in Table 2 decreased the fluorescence intensity (relative value) derived from apoptotic dead cells. Inhibition of increased apoptosis was confirmed in fibroblasts artificially induced by stress.
- Table 3 shows the state of mitochondrial membrane potential by measuring the red fluorescence intensity and the green fluorescence intensity of the cell population to be measured, calculating the value of red fluorescence intensity / green fluorescence intensity, and applying that value to normal cells. It is a table
- surface which shows the relative value by making the measured value made into 1 into 1.
- FIG. we are looking at the recovery effect of the mitochondrial membrane potential, which declines due to aging, and the greater the membrane potential difference, the more energy production in mitochondria and the better the state of the cell, so this value is referred to as the ⁇ mitochondrial function improvement effect '' It was.
- Elastin is a fibrous protein that has the function of linking collagens together and is present in the dermis, blood vessels, and ligaments of the skin, and gives skin elasticity and elasticity. It has been known. The effect of the hydroxycitrate derivative on the production of elastin was verified by the following method. Senescent cells and untreated normal cells prepared in Experimental Example 1 were prepared at a seeding density of 4000 cells / cm 2 and cultured in DMEM medium containing 10% fetal bovine serum for 24 hours.
- Example 4 Usage test Using the formulations A and B in the cream of the formulation example 1 and the formulation C of the comparative example 1, samples were applied to the skin of 20 women (35 to 55 years old) twice a day (morning in the morning) , Evening) It was applied for 2 consecutive months. Judgment is “valid” if the difference between the evaluation point of the test site before starting use and after 2 consecutive months of application is 2 points or more, “slightly valid” if 1 point, “invalid” if 0 point The number of subjects who became “effective” or “somewhat effective” was defined as “improvement effect”.
- the table shows “skin moisture”, “skin smoothness”, and “skin elasticity”. The effect was judged by the number of people who answered each item in 5.
- the test results are shown in Table 6.
- the composition containing the mitochondrial function improving agent according to the present invention shown in Table 1 showed an excellent anti-aging effect on the skin. During the test period, there was no skin problem and there was no problem with safety.
- Mitochondrial function-improving agent capable of improving mitochondrial function, and anti-aging composition that exhibits effects in preventing skin aging and improving symptoms.
Abstract
Description
老化した細胞や紫外線などのストレスによりダメージを受けた細胞において、ミトコンドリアの機能を改善することにより、細胞の賦活化が出来ると考えられる。これまで、ミトコンドリア機能改善剤としてはスフィンゴミエリンや抗酸化物質としてグルタチオンなどが報告されているが(特許文献1、非特許文献4)、その効果はまだ十分ではない。
[1]下記式(I)で示されるヒドロキシクエン酸誘導体又はその塩を有効成分として含有するミトコンドリア機能改善剤;
脂肪族カルボン酸誘導体と前記第一工程で得られた化合物とを反応させ、前記第一工程で得られた化合物の水酸基をエステル化する第二工程と、
前記第二工程で得られた化合物のエステル結合部位のうち、第一工程で形成されたエステル結合部位の一部または全部を切断する第三工程とを有する方法により製造する前記[1]~[6]のいずれか一つに記載のミトコンドリア機能改善剤の製造方法。
また、本発明の老化防止用組成物によれば、シワ、タルミの形成等をはじめとする細胞や皮膚組織の老化の防止又は改善に有用である。
<ヒドロキシクエン酸誘導体又はその塩>
本発明のミトコンドリア機能改善剤は、下記式(I)で示されるヒドロキシクエン酸誘導体又はその塩を有効成分として含有する。
これらのうち、上記式(Ia)で示される群から選択されるいずれかの基は、炭素数8~24、好ましくは炭素数14~22の基であることが望ましい。
R6、R7、R8としては、後に記載のR3,R4,R5,R3',R4',R5'として具体的に示される基を例示できる。
分子中の水酸基が修飾された誘導体の例としては、具体的には、上記式(I)中のR1及び/又はR2が、ヘキサノイル基、2-メチルペンタノイル基、3-メチルペンタノイル基、4-メチルペンタノイル基、2-エチルブタノイル基、ヘプタノイル基、2-メチルヘキサノイル基、3-メチルヘキサノイル基、4-メチルヘキサノイル基、2-エチルペンタノイル基、3-エチルペンタノイル基、オクタノイル基、2-メチルヘプタノイル基、3-メチルヘプタノイル基、4-メチルヘプタノイル基、5-メチルヘプタノイル基、6-メチルヘプタノイル基、2-エチルヘキサノイル基、3-エチルヘキサノイル基、4-エチルヘキサノイル基、2-プロピルペンタノイル基、ノナノイル基、デカノイル基、ウンデカノイル基、10-ウンデセノイル基、ドデカノイル基、トリデカノイル基、テトラデカノイル基、ペンタデカノイル基、ヘキサデカノイル基、9-ヘキサデセノイル基、
ヘプタデカノイル基、オクタデカノイル基、イソステアリル基、シス-9-オクタデセノイル基、11-オクタデセノイル基、シス,シス-9,12-オクタデカジエノイル基、9,12,15-オクタデカトリエノイル基、6,9,12-オクタデカトリエノイル基、9,11,13-オクタデカトリエノイル基、ノナデカノイル基、2,6,10,14-テトラメチルベンタデカノイル基、イコサノイル基、8,11-イコサジエノイル基、5,8,11-イコサトリエノイル基、5,8,11,14-イコサテトラエノイル基、3,7,11,15-テトラメチルヘキサデカノイル基、ヘンイコサノイル基、ドコサノイル基のいずれかである化合物が挙げられる。
X1~X3のいずれかが窒素原子の場合は-CONRmRm'(mおよびm’は、X1~X3に対応して3,4,5のいずれか同じ数を表す。)は置換又は無置換のアミド基を表し、またX1~X3のいずれかが酸素原子の場合は-COORm(mは、X1~X3に対応して3,4,5のいずれかの数を表す。)は、カルボキシル基又はエステル基を表す。
また、分子中のカルボキシル基が修飾された誘導体の例としては、既に述べた分子中の水酸基が修飾された誘導体のカルボキシル基部位の少なくとも1つが、置換又は無置換のアミド基、又はエステル基となっている化合物が挙げられる。
R2が水素原子であり、R3~R5がそれぞれ独立に水素原子又は分岐もしくは不飽和結合を有していてもよい、炭素数1~30の鎖状炭化水素基であり(但し、R3~R5が同時に水素原子となることはない。)、且つX1~X3がすべて酸素原子である下記式(IIb)に示す化合物が好ましい例として挙げられる。
これらの場合、すなわち本発明のミトコンドリア機能改善剤に係るヒドロキシクエン酸誘導体が、下記式(IIa)に示す化合物又は下記式(IIb)に示す化合物である場合、R1は上記式(Ia)で示される群から選択されるいずれかの基を表し、上記式(Ia)で示される基のなかでは、上記式(Ia‐1)で示される基であることが好ましい。さらに式(Ia)において、R6は、分岐、不飽和結合もしくは置換基を有していてもよい、炭素数7~23の鎖状炭化水素基であることが好ましく、炭素数10~22の鎖状炭化水素基であることが好ましく、炭素数13~21の鎖状炭化水素基であることがより好ましく、炭素数13~18の鎖状炭化水素基であることがさらに好ましい。
鎖状炭化水素基としては鎖状飽和炭化水素基であることが好ましく、置換基を有さないことがより好ましい。R6は、置換基を有さない炭素数7~23の鎖状飽和炭化水素基であることが好ましく、置換基を有さない炭素数10~22の鎖状飽和炭化水素基であることが好ましく、置換基を有さない炭素数13~21の鎖状飽和炭化水素基であることがより好ましく、置換基を有さない炭素数13~18の鎖状飽和炭化水素基であることがさらに好ましい。
鎖状炭化水素基としては、直鎖状飽和炭化水素基であることが好ましく、置換基を有さないことがより好ましい。R6は、置換基を有さない炭素数7~23の直鎖状飽和炭化水素基であることが好ましく、置換基を有さない炭素数10~22の直鎖状飽和炭化水素基であることが好ましく、置換基を有さない炭素数13~21の直鎖状飽和炭化水素基であることがより好ましく、置換基を有さない炭素数13~18の直鎖状飽和炭化水素基であることがさらに好ましい。
R1としては、炭素数14~22のアシル基が望ましい。
アルカリ金属塩としては、ナトリウム塩、カリウム塩等が挙げられ、アルカリ土類金属塩としては、カルシウム塩等が挙げられる。
前記ヒドロキシクエン酸誘導体又はその塩の投与量は、ヒドロキシクエン酸誘導体又はその塩の血中濃度又は培養液中濃度によって定めてもよい。例えば、前記ヒドロキシクエン酸誘導体又はその塩の血中濃度又は培養液中濃度(モル比)としては、例えば、0.001μM~100μM程度とすることが好ましく、0.005μM~50μM程度とすることがより好ましく、0.005μM~20μM程度とすることがさらに好ましい。
次に、本発明のミトコンドリア機能改善剤に係るヒドロキシクエン酸誘導体又はその塩の製造方法について説明する。
本発明のミトコンドリア機能改善剤に係るヒドロキシクエン酸誘導体又はその塩の製造方法には特に制限はなく、ヒドロキシクエン酸及び/又はそのアルカリ金属塩及び/又はそのアルカリ土類金属塩と、カルボン酸誘導体又はリン酸誘導体又はスルホン酸誘導体とを、適当な溶媒中で反応させることによって製造することが可能である。
(1)ヒドロキシクエン酸の水酸基を直接エステル化する方法、
(2)ヒドロキシクエン酸のカルボキシル基をエステル化してから、水酸基をエステル化し、前者のエステル結合部位を切断してカルボキシル基に戻す方法、
(3)ヒドロキシクエン酸のカルボキシル基をエステル化してから、水酸基をエステル化する方法、
(4)ヒドロキシクエン酸の水酸基をエステル化してから、カルボキシル基をエステル化する方法、
(5)ヒドロキシクエン酸のカルボキシル基をアミド化してから、水酸基をエステル化する方法、
(6)ヒドロキシクエン酸のカルボキシル基をアミド化してから、水酸基をエステル化し、前者のアミド結合部位を切断してカルボキシル基に戻す方法、
(7)ヒドロキシクエン酸の水酸基をエステル化してから、カルボキシル基をアミド化する方法等を挙げることができる。
これらの製造方法では試薬の使用量を適当に調節し、ヒドロキシクエン酸の2位の水酸基と3位の水酸基の反応性の違いを利用して、2位の水酸基のみを修飾することも可能である。
反応濃度はとくに限定はないが、0.0001mol/dm3~10mol/dm3の範囲が好ましく、0.1mol/dm3~1mol/dm3の範囲がさらに好ましい。
また、このようなpH調節を行うことにより、ヒドロキシクエン酸誘導体の塩を容易に製造することができる。たとえば、pH調整剤としてNaOHを用いれば、ヒドロキシクエン酸誘導体のNa塩を得ることができる。
脂肪族カルボン酸誘導体と前記第一工程で得られた化合物とを反応させ、前記第一工程で得られた化合物の水酸基をエステル化する第二工程と、
前記第二工程で得られた化合物のエステル結合部位のうち、第一工程で形成されたエステル結合部位の一部または全部を切断する第三工程とを有することを特徴とするヒドロキシクエン酸誘導体又はその塩を製造する方法により製造されたものであってもよい。
本発明の老化防止用組成物は、
下記式(I)で示されるヒドロキシクエン酸誘導体又はその塩を有効成分として含有する老化防止用組成物;
陽イオン性界面活性剤では、ベヘントリモニウムクロリド、ステアルトリモニウムクロリド、セトリモニウムクロリド、ラウリルトリモニウムクロリド等のアルキルトリメチルアンモニウムクロリド;ステアリルトリモニウムブロミド等のアルキルトリメチルアンモニウムブロミド;ジステアリルジモニウムクロリド、ジココジモニウムクロリド等のジアルキルジメチルアンモニウムクロリド;ステアラミドプロピルジメチルアミン、ステアラミドエチルジエチルアミン等の脂肪酸アミドアミン及びその塩;ステアロキシプロピルジメチルアミン等のアルキルエーテルアミン及びその塩または四級塩;エチル硫酸長鎖分岐脂肪酸(12~31)アミノプロピルエチルジメチルアンモニウム、エチル硫酸ラノリン脂肪酸アミノプロピルエチルジメチルアンモニウム等の脂肪酸アミド型四級アンモニウム塩;ポリオキシエチレンアルキルアミン及びその塩または四級塩;アルキルアミン塩;脂肪酸アミドグアニジウム塩;アルキルエーテルアンモニウム塩;アルキルトリアルキレングリコールアンモニウム塩;ベンザルコニウム塩;ベンゼトニウム塩;塩化セチルピリジニウム等のピリジニウム塩;イミダゾリニウム塩;アルキルイソキノリニウム塩;ジアルキルモリホニウム塩;ポリアミン脂肪酸誘導体;アミノプロピルジメチコン及びアモジメチコン等のアミノ変性シリコーン、カチオン変性シリコーン、カチオン変性及びポリエーテル変性シリコーン、アミノ変性及びポリエーテル変性シリコーン等のシリコーン系陽イオン性界面活性剤等;ラウリルベタイン(ラウリルジメチルアミノ酢酸ベタイン)等のN-アルキル-N,N-ジメチルアミノ酸ベタイン;コカミドプロピルベタイン、ラウラミドプロピルベタイン等の脂肪酸アミドアルキル-N,N-ジメチルアミノ酸ベタイン;ココアンホ酢酸ナトリウム、ラウロアンホ酢酸ナトリウム等のイミダゾリン型ベタイン;アルキルジメチルタウリン等のアルキルスルホベタイン;アルキルジメチルアミノエタノール硫酸エステル等の硫酸型ベタイン;アルキルジメチルアミノエタノールリン酸エステル等のリン酸型ベタイン;ホスファチジルコリン、ホスファチジルエタノールアミン、ホスファチジルセリン、スフィンゴミエリン等のスフィンゴリン脂質、リゾレシチン、水素添加大豆リン脂質、部分水素添加大豆リン脂質、水素添加卵黄リン脂質、部分水素添加卵黄リン脂質、水酸化レシチン等のリン脂質類;シリコーン系両性界面活性剤等の両性界面活性剤;ポリビニルアルコール、アルギン酸ナトリウム、デンプン誘導体、トラガントガム、アクリル酸・メタアクリル酸アルキル共重合体;シリコーン系各種界面活性剤等の高分子界面活性剤が挙げられる。
水酸化クロム、チタン酸コバルト等の無機緑色系顔料;群青、紺青等の無機青色系顔料;酸化チタンコーテッドマイカ、酸化チタンコーテッドオキシ塩化ビスマス、酸化チタンコーテッドタルク、着色酸化チタンコーテッドマイカ、オキシ塩化ビスマス、魚鱗箔等のパール顔料;アルミニウムパウダー、カッパーパウダー、金等の金属粉末顔料;表面処理無機及び金属粉末顔料;赤色201号、赤色202号、赤色204号、赤色205号、赤色220号、赤色226号、赤色228号、赤色405号、橙色203号、橙色204号、黄色205号、黄色401号、青色404号、赤色3号、赤色104号、赤色106号、赤色227号、赤色230号、赤色401号、赤色505号、橙色205号、黄色4号、黄色5号、黄色202号、黄色203号、緑色3号、青色1号等のジルコニウム、バリウム又はアルミニウムレーキ等の有機顔料;表面処理有機顔料;アスタキサンチン、アリザリン等のアントラキノン類、アントシアニジン、β-カロチン、カテナール、カプサンチン、カルコン、カルサミン、クエルセチン、クロシン、クロロフィル、クルクミン、コチニール、シコニン等のナフトキノン類、ビキシン、フラボン類、ベタシアニジン、ヘナ、ヘモグロビン、リコピン、リボフラビン、ルチン等の天然色素・染料;p-フェニレンジアミン、トルエン-2,5-ジアミン、o-,m-,若しくはp-アミノフェノール、m-フェニレンジアミン、5-アミノ-2-メチルフェノール、レゾルシン、1-ナフトール、2,6-ジアミノピリジン等及びその塩等の酸化染料中間体及びカップラー;インドリン等の自動酸化型染料;ジヒドロキシアセトンが挙げられる。
カリウムミョウバン、酸化カリウム、臭化カリウム、ヨウ化カリウム、硝酸カリウム、硫酸カリウム、硫化カリウム、酢酸カリウム、臭素酸カリウム、塩化カリウム、亜硝酸カリウム、亜硫酸カリウム、ヒ酸カリウム、ヨウ素酸カリウム、水素化カリウム、カリウムt-ブトキシド、炭酸カリウム、塩素酸カリウム、シアン酸カリウム、シアン化カリウム、フッ化カリウム、シュウ酸カリウム、ケイ酸カリウム、亜ヒ酸カリウム、スズ酸カリウム、クロム酸カリウム、水酸化カリウム、リン酸カリウム、ソルビン酸カリウム、重硫酸カリウム、セレン酸カリウム、過硫酸カリウム、ロダン化カリウム、ロサルタンカリウム、亜セレン酸カリウム、亜テルル酸カリウム、ワルファリンカリウム、過ヨウ素酸カリウム、グルコン酸カリウム、カンレノ酸カリウム、過塩素酸カリウム、チオ硫酸カリウム、重クロム酸カリウム、ホウフッ化カリウム、二クロム酸カリウム、モリブデン酸カリウム、ピロ亜硫酸カリウム、アスパラギン酸カリウム、ペミロラストカリウム、次亜塩素酸カリウム、チオシアン酸カリウム、クラブラン酸カリウム、硫酸カリウムアルミニウム、硫シアン化カリウム、水酸化ホウ素カリウム、次亜リン酸カリウム、メタリン酸カリウム、過マンガン酸カリウム、ピロリン酸カリウム、フェリシアン化カリウム、フェロシアン化カリウム、ケイフッ化カリウム、硫酸水素カリウム、メタバナジン酸カリウム、キサントゲン酸カリウム、シュウ酸水素カリウム、クロラゼプ酸二カリウム、セレノシアン酸カリウム、シュウ酸二カリウム、フルオロケイ酸カリウム、スズ酸カリウム三水和物、炭酸水素カリウム、ペルオキソ二硫酸カリウム、硫酸アルミニウムカリウム、ピロリン酸四カリウム、ベンジルペニシリンカリウム、カリウム(メチルスルフィニル)メタニド、リン酸二水素カリウム、リン酸水素二カリウム、グリチルリチン酸二カリウム、テトラフルオロホウ酸カリウム、グアヤコールスルホン酸カリウム、ヘキサフルオロケイ酸カリウム、硫酸カリウムアルミニウム十二水和物、ジチオ炭酸o-エチルカリウム、ヘキサシアノ鉄(III)カリウム、フェノキシメチルペニシリンカリウム、(2E,4E)-2,4-ヘキサジエン酸カリウムなどのカリウム化合物、酸化ルビジウム、臭化ルビジウム、ヨウ化ルビジウム、硫酸ルビジウム、塩化ルビジウム、フッ化ルビジウム、酢酸ルビジウム、硫酸水素ルビジウム、炭酸ジルビジウムなどのルビジウム化合物、セシウムシアニド、酸化セシウム、臭化セシウム、ヨウ化セシウム、硝酸セシウム、硫酸セシウム、塩化セシウム、炭酸セシウム、フッ化セシウム、炭酸ジセシウム、シュウ酸ジセシウム、硫酸二セシウム、L-酒石酸ジセシウム、水酸化セシウム一水和物、トリフルオロ酢酸セシウム、2,3-ジヒドロキシブタン二酸1-セシウム、2,3-ジヒドロキシブタン二酸水素1-セシウムなどがのセシウム化合物、酸化ベリリウム、臭化ベリリウム、炭化ベリリウム、ヨウ化ベリリウム、硝酸ベリリウム、窒化ベリリウム、硫化ベリリウム、塩化ベリリウム、フッ化ベリリウム、ケイ酸ベリリウム、ジステアリン酸ベリリウム、硫酸ベリリウム四水塩、アセチルアセトンベリリウム塩などのベリリウム化合物、酸化マグネシウム、マグネシウムオロテート、アリールマグネシウム、酢酸マグネシウム、ホウ化マグネシウム、臭化マグネシウム、炭化マグネシウム、ヨウ化マグネシウム、硝酸マグネシウム、窒化マグネシウム、硫酸マグネシウム、硫化マグネシウム、マグネシウム(粉末)、塩化マグネシウム、炭酸マグネシウム、塩素酸マグネシウム、クエン酸マグネシウム、フッ化マグネシウム、ケイ酸マグネシウム、ケイ化マグネシウム、水酸化マグネシウム、リン化マグネシウム、オロチン酸マグネシウム、硝酸マグネシウム(II)、ステアリン酸マグネシウム、過塩素酸マグネシウム、ミリスチン酸マグネシウム、シュウ酸マグネシウム、炭酸水素マグネシウム、ケイフッ化マグネシウム、フルオロケイ酸マグネシウム、臭化フェニルマグネシウム、硝酸マグネシウム六水和物、フタロシアニンマグネシウム、酢酸マグネシウム四水和物、安息香酸マグネシウム三水和物、炭酸カルシウムマグネシウム、クロム酸マグネシウム五水和物、ヘキサフルオロケイ酸マグネシウム、メタケイ酸アルミン酸マグネシウム、ケイ酸アルミン酸マグネシウムビスマス、水酸化アルミニウムマグネシウム炭酸塩水和物などのマグネシウム化合物、カルシウムカーバイド、酸化カルシウム、臭化カルシウム、炭化カルシウム、カルシウムシアナミド、ヨウ化カルシウム、乳酸カルシウム、硝酸カルシウム、窒化カルシウム、硫酸カルシウム、硫化カルシウム、酢酸カルシウム、塩化カルシウム、亜硝酸カルシウム、亜硫酸カルシウム、ヒ酸カルシウム、水素化カルシウム、砒酸カルシウム、ヨウ素酸カルシウム、炭酸カルシウム、塩素酸カルシウム、フッ化カルシウム、シュウ酸カルシウム、過酸化カルシウム、ケイ酸カルシウム、ケイ化カルシウム、シアン化カルシウム、亜ヒ酸カルシウム、ヘパリンカルシウム、亜塩素酸カルシウム、クロム酸カルシウム、水酸化カルシウム、リン酸カルシウム、リン化カルシウム、ホリナートカルシウム、グルコン酸カルシウム、ステアリン酸カルシウム、アスパラギン酸カルシウム、次亜塩素酸カルシウム、ホスホマイシンカルシウム、メタケイ酸カルシウム、チオシアン酸カルシウム、次亜リン酸カルシウム、パントテン酸カルシウム、過マンガン酸カルシウム、フェノプロフェンカルシウム、塩化カルシウム二水和物、炭酸カルシウムマグネシウム、ポリカルボフィルカルシウム、ムピロシンカルシウム水和物、リン酸水素カルシウム、グリセロリン酸カルシウム、ジヨードステアリン酸カルシウム、沈降炭酸カルシウム、エデト酸二ナトリウムカルシウム、アトルバスタチンカルシウム水和物、(+)-パントテン酸カルシウム、パラアミノサリチル酸カルシウム、コハク酸トコフェロールカルシウム、ポリスチレンスルホン酸カルシウム、(+)-パントテン酸カルシウム塩(2:1)、アルミノパラアミノサリチル酸カルシウム、3-ヒドロキシ-4-[(4-メチル-2-スルホフェニル)アゾ]-2-ナフタレンカルボン酸カルシウム塩などのカルシウム化合物、酸化バリウム、アジ化バリウム、酢酸バリウム、臭化バリウム、ヨウ化バリウム、硝酸バリウム、窒化バリウム、硫酸バリウム、硫化バリウム、ギ酸バリウム、乳酸バリウム、塩化バリウム、亜硫酸バリウム、炭酸バリウム、塩素酸バリウム、フッ化バリウム、過酸化バリウム、シアン化バリウム、クロム酸バリウム、水酸化バリウム、チタン酸バリウム、セレン酸バリウム、リン酸バリウム、硝酸バリウム(II)、亜セレン酸バリウム、マンガン酸バリウム、シュウ酸バリウム、ステアリン酸バリウム、過塩素酸バリウム、チオ硫酸バリウム、次亜塩素酸バリウム、過マンガン酸バリウム、クロラニル酸バリウム、塩化バリウム二水和物、二酢酸バリウム、臭化バリウム二水和物、ジプロピオン酸バリウム、塩素酸バリウム一水和物、水酸化バリウム八水和物、チオシアン酸バリウム二水和物、チオ硫酸バリウム一水和物、アセチルアセトンバリウム二水和物などのバリウム化合物が挙げられる。
本発明の老化防止用組成物が化粧料である場合、さらに、既存の化粧品原料を一般的な濃度で添加することもできる。たとえば、化粧品原料基準第二版注解、日本公定書教会編、1984(薬事日報社)、化粧品原料基準外成分規格、厚生省薬務局審査課監修、1993(薬事日報社)、化粧品原料基準外成分規格追補、厚生省薬務局審査課監修、1993(薬事日報社)、化粧品種別許可基準、厚生省薬務局審査課監修、1993(薬事日報社)、化粧品種別配合成分規格、厚生省薬務局審査課監修、1997(薬事日報社)、および化粧品原料辞典、平成3年(日光ケミカルズ)等に記載されている全ての化粧品原料を使用することができる。
本発明の老化防止用組成物のpHは、6~9であることが好ましく、pH7~8.5であるとさらに好ましい。pHがこの範囲内であると、ヒドロキシクエン酸誘導体の安定性が良好で、製剤安定性もより良好となる。なお該pHは、約25℃における値である。
本発明に係るヒドロキシクエン酸誘導体を含む製剤は、処方例として下記(表1)に示す処方に沿って、製剤化を行うことができる。
処方例1 クリーム
成分Aを85oCに加温、混合後、ホモミキサーにかけながら、成分Bを85oCに加温、混合したものを徐々に添加した。60oCまで放冷し、その後冷却し、30oCまで攪拌した。
処方例1において、ヒドロキシクエン酸誘導体を精製水に置き換えた処方3を従来のクリームとした。
ヒト皮膚由来線維芽細胞NB1-RGB細胞におけるミトコンドリア機能改善効果を、ミトコンドリア膜電位を指標に下記の条件にて測定した。
コンフルエントな状態のNB1-RGB細胞に600 μM 過酸化水素水を含む10 %ウシ胎児血清を含むD M E M 培地にて1 時間培養する操作を4日間行うことで、人工的に酸化的老化を誘導した細胞を老化細胞とした。この老化細胞と未処理の正常細胞を、4000個/cm2の播種密度で準備し10 %ウシ胎児血清を含むDMEM培地にて24時間培養した。10 %ウシ胎児血清を含むDMEM培地に、試料として、終濃度0μM(コントロール)、又は10μMとなるように50%エタノールに溶かした本発明に係るヒドロキシクエン酸誘導体添加して48 時間培養した。蛍光物質5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazoilcarbocyanine iodide(JC-1)は、膜電位が高いほどミトコンドリアに多く取り込まれ、生細胞では赤色の蛍光を発し、膜電位が低いとミトコンドリアに取り込まれず、アポトーシスによる死細胞では緑色の蛍光を発する。このCayman社が提供するJC-1 Mitochondrial Membrane Potential Assay Kitを用い、JC-1を培地に10%濃度で添加し、15分間培養した後、400gで5分間遠心した。さらに、キット添付のアッセイ溶液に培地を置換した後、400gで5分間遠心することを2回繰り返した。新たな、キット添付のアッセイ溶液に置換後、励起520~570 nm /蛍光570~610 nmで生細胞を,励起485 nm /蛍光535 nmで死細胞の蛍光強度を測定した。
表2に示す結果を参照すると、表2に示す本発明に係るヒドロキシクエン酸誘導体の添加によって、アポトーシスを起こした死細胞由来の蛍光強度(相対値)が低下したことから、過酸化水素による酸化ストレスで人工的に老化を誘導した繊維芽細胞において増加するアポトーシスに対する抑制作用が確認された。
ここでは、老化により下がるミトコンドリア膜電位の回復効果をみており、膜電位差が大きいほどミトコンドリアでのエネルギー産生量が多く細胞の状態が健康であるといえることから、この値を「ミトコンドリア機能改善効果」とした。
エラスチンは、主にコラーゲン同士を結びつける働きを持つ繊維状のたんぱく質で、皮膚の真皮や血管、靭帯などに存在し、肌にハリや弾力を与えることが知られている。このエラスチンの産生に対するヒドロキシクエン酸誘導体の効果を以下の方法で検証した。
実験例1で作製した老化細胞と未処理の正常細胞を、4000個/cm2の播種密度で準備し10%ウシ胎児血清を含むDMEM培地にて24時間培養した。10% ウシ胎児血清を含むDMEM培地に、終濃度0μM(コントロール)、0.01μM、又は0.1μMとなるように50%エタノールに溶かした本発明に係るヒドロキシクエン酸誘導体を添加して48 時間培養した。その後細胞を回収し、Biocolor社製のエラスチン測定キットにてエラスチンを抽出し、抽出液の波長513nmの吸光度を測定した。
処方例1のクリームにある処方AおよびBと比較例1の処方Cを用いて、各々女性20人(35~55才)の肌に試料を1日2回(朝、夕)連続2ケ月間塗布した。判定は使用開始前と2ヶ月連続塗布後の試験部位の評価点との差が2 点以上の場合を「有効」、1点の場合を「やや有効」、0点の場合を「無効」とし、「有効」または「やや有効」となった被験者の人数を「改善効果」とした。それぞれ老化防止効果の典型的な官能指標と考えられる皮膚の湿潤性、平滑性、弾力性の各項目に対して、「皮膚の潤い」、「皮膚の滑らかさ」、「皮膚のハリ」について表5にあるそれぞれの項目に回答した人数で、効果を判定した。
Claims (9)
- 下記式(I)で示されるヒドロキシクエン酸誘導体又はその塩を有効成分として含有するミトコンドリア機能改善剤;
- 前記式(Ia)中、R6が、分岐、不飽和結合もしくは置換基を有していてもよい、炭素数7~23の鎖状炭化水素基であり、R7及びR8が、それぞれ独立に、水素原子、又は分岐、不飽和結合もしくは置換基を有していてもよい、炭素数8~24の鎖状炭化水素基である請求項1に記載のミトコンドリア機能改善剤。
- 前記式(I)中、X1~X3がすべて酸素原子であり、R3~R5が、それぞれ独立に水素原子、又は分岐もしくは不飽和結合を有していてもよい、炭素数1~30の鎖状炭化水素基であり、且つ、前記式(Ia)中、R6が、分岐、不飽和結合もしくは置換基を有していてもよい、炭素数7~23の鎖状炭化水素基であり、R7及びR8が、それぞれ独立に、水素原子、又は分岐、不飽和結合もしくは置換基を有していてもよい、炭素数8~24の鎖状炭化水素基である請求項1に記載のミトコンドリア機能改善剤。
- 前記式(I)中、R2が水素原子であり、X1~X3がすべて酸素原子であり、R3~R5がすべて水素原子であり、且つ、前記式(Ia)中、R6が、分岐、不飽和結合もしくは置換基を有していてもよい、炭素数13~21の鎖状炭化水素基である請求項1に記載のミトコンドリア機能改善剤。
- 前記式(I)中、R2が水素原子であり、X1~X3がすべて酸素原子であり、R3~R5がそれぞれ独立に水素原子、又は分岐もしくは不飽和結合を有していてもよい、炭素数1~30の鎖状炭化水素基であり(但し、R3~R5が同時に水素原子となることはない。)、且つ、前記式(Ia)中、R6は、分岐、不飽和結合もしくは置換基を有していてもよい、炭素数13~21の鎖状炭化水素基である請求項1に記載のミトコンドリア機能改善剤。
- ヒドロキシクエン酸の誘導体またはその塩を、ヒドロキシクエン酸及び/又はそのアルカリ金属塩及び/又はそのアルカリ土類金属塩と、カルボン酸誘導体又はリン酸誘導体又はスルホン酸誘導体とを溶媒中で反応させることによって製造することを含む請求項1に記載のミトコンドリア機能改善剤の製造方法。
- ヒドロキシクエン酸の誘導体またはその塩を、ヒドロキシクエン酸及び/又はそのアルカリ金属塩及び/又はそのアルカリ土類金属塩を溶媒中でアルコールと反応させ、ヒドロキシクエン酸(トリ)エステルを製造する第一工程と、
脂肪族カルボン酸誘導体と前記第一工程で得られた化合物とを反応させ、前記第一工程で得られた化合物の水酸基をエステル化する第二工程と、
前記第二工程で得られた化合物のエステル結合部位のうち、第一工程で形成されたエステル結合部位の一部または全部を切断する第三工程とを有する方法により製造する請求項1に記載のミトコンドリア機能改善剤の製造方法。 - 下記式(I)で示されるヒドロキシクエン酸誘導体又はその塩を有効成分として含有する老化防止用組成物;
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15854398.3A EP3213739A4 (en) | 2014-10-29 | 2015-10-20 | Agent for improving mitochondrial function and anti-aging composition |
US15/521,464 US20170312200A1 (en) | 2014-10-29 | 2015-10-20 | An agent for improving mitochondrial function |
JP2016550279A JPWO2016067968A1 (ja) | 2014-10-29 | 2015-10-20 | ミトコンドリア機能改善剤 |
CN201580057875.8A CN107106430A (zh) | 2014-10-29 | 2015-10-20 | 线粒体功能改善剂及老化防止用组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-220578 | 2014-10-29 | ||
JP2014220578 | 2014-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016067968A1 true WO2016067968A1 (ja) | 2016-05-06 |
Family
ID=55857309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/079543 WO2016067968A1 (ja) | 2014-10-29 | 2015-10-20 | ミトコンドリア機能改善剤、及び老化防止用組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20170312200A1 (ja) |
EP (1) | EP3213739A4 (ja) |
JP (2) | JPWO2016067968A1 (ja) |
CN (1) | CN107106430A (ja) |
WO (1) | WO2016067968A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018123130A (ja) * | 2017-02-01 | 2018-08-09 | ロート製薬株式会社 | 美容組成物及びミトコンドリアトランスファー促進剤 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018049216A1 (en) | 2016-09-08 | 2018-03-15 | Glykon Technologies Group, Llc | Monomeric bimetal hydroxycitric acid compounds and methods of making and using the same |
CN109594196A (zh) * | 2018-11-07 | 2019-04-09 | 桐城市鸿江包装有限公司 | 抗菌型墙布用无纺布的制备方法 |
CN110403893A (zh) * | 2019-08-06 | 2019-11-05 | 江苏蜂奥生物科技有限公司 | 一种含有蜂胶提取物的洁面乳 |
CN110530834B (zh) * | 2019-08-28 | 2021-08-03 | 西南交通大学 | 一种快速高效检测痕量对苯二胺的方法 |
KR102088694B1 (ko) * | 2019-11-19 | 2020-03-16 | 최성현 | 한방 마스크 및 이의 제조방법 |
KR20220122693A (ko) * | 2019-12-27 | 2022-09-02 | 산토리 홀딩스 가부시키가이샤 | 세사민류 및 pqq를 함유하는 조성물 |
CN111440767B (zh) * | 2020-04-24 | 2023-07-21 | 尚禾粒线体生物科技(深圳)有限公司 | 一种线粒体保护剂及其应用 |
TW202325331A (zh) * | 2021-11-01 | 2023-07-01 | 日商小林製藥股份有限公司 | 醫藥或食品組成物 |
CN115488985B (zh) * | 2022-09-21 | 2023-10-27 | 上海康拜环保设备有限公司 | 一种桉树皮制无甲醛人造板的制造方法 |
CN116622588B (zh) * | 2023-06-30 | 2024-03-12 | 广州播恩维生素有限公司 | 一种饲用乳酸菌制剂保存载体及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007031415A (ja) * | 2004-09-24 | 2007-02-08 | Showa Denko Kk | ヒドロキシクエン酸誘導体類及びこれを含む皮膚外用剤 |
JP2007254387A (ja) * | 2006-03-23 | 2007-10-04 | Showa Denko Kk | 抗老化化粧料 |
JP2014114291A (ja) * | 2013-12-13 | 2014-06-26 | Showa Denko Kk | 化粧料または皮膚外用剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007254395A (ja) * | 2006-03-23 | 2007-10-04 | Showa Denko Kk | メイクアップ化粧料製造のためのヒドロキシクエン酸誘導体又はその塩の使用 |
JP2007254382A (ja) * | 2006-03-23 | 2007-10-04 | Showa Denko Kk | 皮膚収斂剤製造のためのヒドロキシクエン酸誘導体又はその塩の使用 |
JP5634731B2 (ja) * | 2010-03-31 | 2014-12-03 | 日本メナード化粧品株式会社 | 皮膚外用剤 |
JP2015127315A (ja) * | 2013-12-28 | 2015-07-09 | 日本メナード化粧品株式会社 | 痩身方法 |
-
2015
- 2015-10-20 JP JP2016550279A patent/JPWO2016067968A1/ja active Pending
- 2015-10-20 EP EP15854398.3A patent/EP3213739A4/en not_active Withdrawn
- 2015-10-20 WO PCT/JP2015/079543 patent/WO2016067968A1/ja active Application Filing
- 2015-10-20 CN CN201580057875.8A patent/CN107106430A/zh active Pending
- 2015-10-20 US US15/521,464 patent/US20170312200A1/en not_active Abandoned
-
2017
- 2017-01-20 JP JP2017008866A patent/JP6275296B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007031415A (ja) * | 2004-09-24 | 2007-02-08 | Showa Denko Kk | ヒドロキシクエン酸誘導体類及びこれを含む皮膚外用剤 |
JP2007254387A (ja) * | 2006-03-23 | 2007-10-04 | Showa Denko Kk | 抗老化化粧料 |
JP2014114291A (ja) * | 2013-12-13 | 2014-06-26 | Showa Denko Kk | 化粧料または皮膚外用剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3213739A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018123130A (ja) * | 2017-02-01 | 2018-08-09 | ロート製薬株式会社 | 美容組成物及びミトコンドリアトランスファー促進剤 |
Also Published As
Publication number | Publication date |
---|---|
CN107106430A (zh) | 2017-08-29 |
EP3213739A1 (en) | 2017-09-06 |
JP6275296B2 (ja) | 2018-02-07 |
JP2017066167A (ja) | 2017-04-06 |
US20170312200A1 (en) | 2017-11-02 |
EP3213739A4 (en) | 2018-05-30 |
JPWO2016067968A1 (ja) | 2017-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6275296B2 (ja) | ミトコンドリア機能改善剤、及び製造方法 | |
WO2016076310A1 (ja) | 保湿剤 | |
EP3185850B1 (en) | Skin color-improving agent and composition for improving skin color | |
WO2016067688A1 (ja) | 皮膚バリア機能改善剤及び皮膚バリア機能改善用組成物 | |
JP2016222612A (ja) | 化粧料または皮膚外用剤 | |
JP2014114291A (ja) | 化粧料または皮膚外用剤 | |
JP2014114289A (ja) | 化粧料または皮膚外用剤 | |
JP2014114290A (ja) | 化粧料または皮膚外用剤 | |
JP5113371B2 (ja) | シロキクラゲ由来水溶性多糖類の加水分解物、及びこれを含有する抗酸化剤並びに化粧料又は皮膚外用剤、食品 | |
JP5334511B2 (ja) | 化粧料 | |
JP2007137847A (ja) | オリゴマーエステル及びこれらを含有する化粧料及び皮膚外用剤 | |
JP5690074B2 (ja) | セラミド誘導体を含有する化粧料 | |
JP2009057350A (ja) | 抗菌剤及びこれを含有する抗菌性の化粧料又は皮膚外用剤 | |
WO2014115726A1 (ja) | 抗菌性組成物 | |
JP2010265189A (ja) | 抗菌性化粧料 | |
JP5726481B2 (ja) | ヒドロキシニコチン酸又はその誘導体を含有する化粧料又は皮膚外用剤 | |
JP7309428B2 (ja) | ホスファチジルイノシトール含有化粧料又は皮膚外用剤 | |
JP2013049633A (ja) | ラメラ形成能を有する化粧料又は皮膚外用剤用のジエステル組成物 | |
JP5602456B2 (ja) | アスコルビン酸誘導体 | |
JP2014210711A (ja) | ヒアルロン酸産生促進剤 | |
JP2007137848A (ja) | 化粧料及び皮膚外用剤 | |
JP2013173683A (ja) | 乳酸、又は、乳酸及びヒドロキシステアリン酸の低重合物からなる化粧料用組成物 | |
JP2010229074A (ja) | アスコルビン酸誘導体 | |
JP2016047807A (ja) | マンダリンオレンジ抽出物含有アデノシン三リン酸フォスファターゼ発現誘導剤 | |
WO2016031079A1 (ja) | フェニルエチルアミン誘導体又はシネフリン含有アデノシン三リン酸フォスファターゼ発現誘導剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15854398 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016550279 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015854398 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15521464 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |